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CHAPTER 1: Introduction
1.1 Pancreatic Cancer:
Pancreatic Cancer is one of the most aggressive cancer types with < 6% survival
rate. According to the National cancer Institute it is expected that 45,220 men and
women will be diagnosed with pancreatic cancer and 38,460 men and women will die of
cancer of the pancreas in 2013. While the death rate for other cancer types has
decreased, the upward trend for pancreatic cancer is alarming and calls for biomarker
research, diagnosis and drug discovery for this complicated disease.
The

most

common

type

of

pancreatic

cancer

is

pancreatic

ductal

adenocarcinoma, which accounts for 95 percent of all pancreatic cancer cases. The
remaining 5 percent include other tumors of the exocrine pancreas, acinar cell, and
pancreatic neuroendocrine cells which generally have a much different diagnostic and
therapeutic profile and a more favorable prognosis. Several studies have shown that the
risk of developing pancreatic cancers increases with age, smoking, type2 diabetes and
obesity. The symptoms of pancreatic ductal adenocarcinoma are primarily caused by
mass effect rather than disruption of exocrine or endocrine function [1]. These include
jaundice, loss of appetite, abdominal pain, nausea and unexplained weight loss. Since
these symptoms are non-specific, pancreatic cancer often goes undetected. At present
since there is no specific diagnostic procedure for early detection of pancreatic cancers,
most cases when diagnosed are in advanced stages. Tumors of head of pancreas are
more common as compared to tumors of the body and tail and cause more problems
like biliary duct obstruction and Jaundice. Presently, surgical resection with adjuvant
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chemotherapy is the only curative procedure for patients with pancreatic cancer.
However, this is only possible for 20% of diagnosed cases of pancreatic cancer [1].
Many drugs and chemotherapeutic regimens, both single and multi-agent are being
studied; but with no survival or clinical benefit. Gemcitabine, fluorouracil monotherapy
and leucovorin are being used for treatment with little benefit in advanced cases of
pancreatic cancer[2]. Intra-operative radiation therapy has shown to decrease
progression of locally advanced disease, but have no effects on metastasized cancer,
or survival rate. On the bright side a combination of both radiation therapy and
fluorouracil-based chemotherapy has shown significant improvement in survival rate,
around 40 percent for combination compared to 10 percent for radiation alone after
one year [1]. Research advances into the pathogenesis of pancreatic cancer have led to
a better understanding of the types of pathways involved. Drugs or agents that may
target one or more of the mechanisms underlying the development and progression of
this disease may be beneficial.

1.2 Bioactive food components and Pancreatic cancer:
Recent interest is shifting towards natural compounds present in botanicals and
herbs. Natural extracts and compounds have been shown to have medicinal properties
since centuries. Bioactive food components and nutraceuticals comprise of large groups
of food, or parts of foods that have shown therapeutic health benefits for many
diseases. Recently, some of the natural extracts and functional compounds have shown
promising results in pancreatic cancer research without added side effects [3]. The
range of bioactive food components with potential anti-cancer benefits is numerous.
These agents possess antioxidant, anti-inflammatory, pro-apoptotic and anti-angiogenic
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effects which can inhibit the initiation, promotion and metastatic phases of pancreatic
cancer respectively.
Based on various clinical trials, the efficacy of these compounds has been
proven both invitro and invivo. It is important to mention that most bioactive food
components are pleotropic in nature, capable of acting at different stages of cancer
progression and are not limited to a single mechanism. A number of these components
like lycopene, vitamin A, vitamin C and selenium have antioxidant effects and can help
in arresting pancreatic cancer at the initiation phase of pancreatic carcinogenesis [4].
Anti-apoptotic and inflammatory properties of curcumin, Garcinol and resveratrol can
provide a good line of defense during the promotion phase as well as inhibit angiogenic
factors, preventing metastasis and invasion. Once the cancer is metastasized, these
agents such as omega 3 in fish oil and aged garlic extract can prolong survival,
decrease cachexia and improve the quality of life in patients with advanced cases of
pancreatic cancer. Some of these bioactive food components such as curcumin,
isoflavones and lycopene have passed the phase I clinical trials and are in phase II with
different cancer types, including pancreatic cancer phase ll trial with curcumin [5, 6].
The synergistic effects of these components, among themselves and with
pharmaceutical drugs have opened new doors for cancer management. Studies have
shown some beneficial interaction of two of more of food components on the incidence
of pancreatic carcinomas. The synergistic interaction of curcumin and isoflavone
showed significant inhibition of cell proliferation, apoptosis, and levels of NFkB than
compared to single agents alone [7]. Other studies showed that the combination of
vitamin C, vitamin E, β-carotene and selenium significantly reduced pancreatic cancer
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incidence[4]. Combination of gemcitabine (the current chemotherapeutic drug for
pancreatic cancer) curcumin [8] and resveratrol [9]showed a significant reduction in cell
proliferation, increased apoptosis, reduced angiogenesis and invasion.

Synergistic

effects of curcumin and Garcinol on pancreatic cancer cell lines,

have been

documented by our lab [10]. In addition it was reported that Garcinol showed synergism
with drug of choice gemcitabine in pancreatic cancer cell lines and these results were
more pronounce in Panc 1 kras mutated cell line[11].

1.3 Garcinol a potential anticancer agent:
Garcinol or camboginol is extracted from the rind of fruit of Garcinia indica
(Kokum or Mangosteen). It has been used in the Indian subcontinent, far-east Asia and
Africa for centuries. Garcinol is known for its medicinal properties in home remedies and
Ayurvedic system of medicine [12]. Garcinol and isogarcinol are the benzophenone
derivatives of the fruit extract. Citric acid, Hydroxycitric acid (HCA), hydroxycitric acid
lactone and oxalic acid are also active components of the extract.[12]. Garcinol and
isogarcinol have shown to have antioxidant properties attributed to its structure. The
fruit extract also has hypocholesterolemic and anti-obesity effects due to its HCA
component.
Chemically Garcinol (C38H50O6 ) is a yellow crystalline compound with molecular
weight 602. Its antioxidant properties are due to both hydroxyl groups and β-diketone
moiety[13]. This structure is similar to some antioxidants, Rao et al. determined the
location of terminal alkene in and the presence of a β-diketone in Garcinol [13].
Isogarcinol or cambogin is formed after the terminal alkene undergo cyclization in acidic
conditions[14]. The oxidized isomer isogarcinol is related to its properties as
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antibacterial, antiulcer antiviral and anti-obesity agent [15]. Structure of Garcinol is
similar to many naturally occurring phytochemicals like curcumin, chalcones and
oblogifolins reported to have anti-carcinogenic activity [16, 17].
Garcinol is known for its microbial properties due to its use in traditional
medicine. Garcinol has shown to affect negatively a whole spectrum of microbiota
growth including fungi [18]. Antioxidant properties of Garcinol have been evaluated in
various research studies, Garcinol retarded same amount of superoxide ion as DLalpha-tocopherol in hypoxanthine/xanthine oxidase system. In an indometacin induced
acute ulcer rat model oral Garcinol prevented formation of ulcers [19]. Neuroprotective
properties of Garcinol in rat cortical neuron cultures via preventing nitric oxide (NO)
accumulation in astrocytes have been reported [20].
In recent studies potential role of Garcinol as anticancer agent has been
elucidated. It has shown its efficacy due to its pleotropic nature. As an antioxidant and
anti-inflammatory agent it has shown an increase in liver detoxifying enzymes,
glutathione S-transferase (GST) and quinone reductase (QR) levels, after feeding
Garcinol in azoxymethane (AOM) induced colon cancer rat model, with reduction in
colonic aberrant crypt foci (ACF) [21, 22]. Additionally it has inhibited O2-, Nitric Oxide
(NO), iNOS, and COX2 at comparable or better than epigallocatechingallate (EGCG),
a green tea polyphenol [21]. COX-2 levels were also reduced in male F344 rats in 4nitroquinoline 1-oxide (4-NQO) induced tongue lesions, with dietary Garcinol
administration [23]. Another study has shown reduction of arachidonic acid and its
metabolites in the intestinal and macrophage cell lines investigated. They also reported
reduction in NFκB and COX-2 expressions [24].

6
Apoptotic pathways were also reported to be target of Garcinol in some invitro
studies. There was up-regulation of proapototic Bax and Bad proteins with subsequent
down-regulation of proapototic Bcl2 along with activation of caspase-3,in human
leukemia HL-60 cells resulting in release of cytochrome C from mitochondria [25].
Increase in activity of Caspase-3 is also explained in colon and breast cancer cell lines
[26, 27]. Garcinol has also shown induction of death receptors DR4 and DR5 in various
cancer cell lines [28]. Molecular targets of Garcinol are highlighted in Figure 1
Garcinol is established as a potent histone acetyl-transferase (HAT) inhibitor. It
has been reported to inhibit HATs p300 and PCAF, and can therefore cause epigenetic
suppression to gene transcription [29]. Post transcriptional regulation of genes by
miRNA can effect cancer cell growth and proliferation at different levels. In a recent
study done on human pancreatic cancer cell lines, (BxPC-3 and Panc-1) in our lab,
Garcinol has shown modulation of microRNA molecules in favorable manner[11].
Invitro studies have shown positive effects of Garcinol on most of the cancer cell
lines tested, but there are very few animal studies using this bioactive food component
invivo. The physiological barriers, bioavailability and metabolism of the compound
tested complicate the translation of similar effects invivo. In this study we investigated
the effects of Garcinol in Pancreatic cancer transgenic mouse model (KPC).
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Figure 1: Molecular targets of Garcinol [30]
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Hypothesis
Dietary Garcinol treatment will slow down the progression of
Pancreatic Cancer in Kras and p53 transgenic Pancreatic Cancer mouse
model.
Specific Aim 1:
To investigate the invivo response of dietary Garcinol on PaCa in mouse
model.
1a, To monitor tumor progression with MRI.
1b, To evaluate possibility of toxicity of dietary Garcinol by blood smears and fore
-stomach Hematoxylin and eosin slides (H&E).
1c, Histological evaluation of formalin fixed pancreatic tissue.
The purpose of this aim was to study the development and advancement of
Pancreatic cancer in this mouse model and to investigate the favorable or unfavorable
effects of dietary Garcinol. Pancreatic cancer transgenic mice were fed Garcinol diet or
Isocaloric diet. MRI is a technique used to monitor cancer progression at different time
points in this study. Basement membrane and the lining of fore stomach is normally
hypertrophied with the ingestion of toxic substances and blood smears can provide us
the insight of RBC and WBC changes in control and treatment groups. RBC changes
including basophilic stippling and Heinz bodies can be an effect of toxicity, whereas
WBC type and count provide information about the immune status of the animal.
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Histological part of this aim was to evaluate the status of neoplastic pancreatic
lesions at histological level. We graded the Pancreatic intraepithelial Neoplasia (PanIN)
based on morphology and criteria set by reference [31].

Specific aim 2:
To investigate the mouse pancreatic and liver tissue, for response to the
dietary Garcinol at molecular level.
2a, To explore the change in the micro RNA profile of Garcinol treated vs. control
animals.
2b, Real time Reverse Transcriptase PCR analysis (RTPCR) of tumor related
and miRNA target genes in mouse pancreatic tissue.
2c, Real time Reverse Transcriptase PCR analysis tumor related and miRNA
target genes in common metastatic site liver.
An important part of this aim was to investigate the changes in miRNA array
analysis upon intervention with Garcinol. Garcinol has shown promising results
previously reported invitro data by modulating the tumor promoter and tumor suppressor
markers genes. These pathways were further investigated by measuring relative gene
expressions by RT PCR in Pancreatic tissue. Since the liver is the primary or first site
for metastasis, gene modulation in the liver tissue was also investigated by RTPCR.
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Specific aim 3:
Metabolomic Analysis of Urine samples from treated and untreated groups.
3a, To investigate the differences in Urinary Metabolomic profiles of cancer
control and Garcinol treated mice using Simca P+ software for multivariate data analysis
3b, To conduct target analysis to identify and quantify the differences in
metabolite concentrations:
Urinary metabolomic profiling is a non-invasive approach to study the effects of
any intervention. In this study we used this approach to investigate the changes in
metabolomic profiles of the Garcinol treated Pancreatic cancer mice. Urinary NMR
Spectra were processed and then subjected to multivariate statistical analysis to study
similarities and differences based on variation in metabolite concentrations. Target
analysis of the peaks/metabolites corresponding to the change, metabolites were
identified and quantified using CHENOMX NMR suite.

Animals:
Mice for this study were obtained from Van Andel Institute Grand Rapids under
mutual transfer agreement. The protocol for this project is approved by Department of
Laboratory animal resources (DLAR) and all the mice were housed at Scott Hall DLAR
facility

Protocol number: IACUC Protocol A 06-13-1.
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1.4 KPC mice, clinically relevant mouse model for Pancreatic
Cancer:
Kras and P53 conditional mutant mice (KPC) are clinically relevant model for
pancreatic ductal adenocarcinoma as it develops full range of Pancreatic intraepithelial
neoplasia (PanIN) and aggressive ductal adenocarcinoma with 100% penetrance.
Orthotropic and Xenograft models of pancreatic cancer cannot fully explain the
complexity of development of pancreatic ductal adenocarcinoma (PDA) and are
therefore not true representative of the disease. Specifically the implanted tumor is not
treated as primary tumor by the body and there may not face physiological challenges
which are normally present with development of primary tumor. Typically in PDA, Kras
is mutated (constantly turned on) in 90% of the cases, P53 is mutated (turned off) in
75% of the cases and SMAD 4 or DPC4 (turned off) is mutated in 55% of the cases
[32].

According to Hruban et al (2000) more advanced PanIN accumulate more

mutations and higher instability [32].

Higher Nuclear cytoplasmic ratio, genomic

instability and abnormal mitosis are all hallmarks of carcinogenesis. KPC mice (Figure
2) are Kras, and p53 conditional mutant mice and with Pdx cre recombinase
(krasLSL.G12D/+; p53R172H/+; PdxCretg/+). Pancreatic and duodenal homeobox
(Pdx) is a protein expressed during embryonic development of the pancreas.
Association with Pdx makes these mutations to appear only in the pancreatic tissue
sparing rest of the body. Higher genomic instability, abnormal mitosis, anaphase
bridges and more centrosomes were observed in this model. These mice develop ductal
metaplasia, different stages of PanINs, ductal adenocarcinoma and macro-metastasis
[32].

Median

survival

rate

is 4.5

month

[33].

Therefore

Pancreatic ductal
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adenocarcinoma in KPC mice resembles human tumors both patho-physiologically and
at the molecular level [33].
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CHAPTER 2: Dietary Garcinol Arrests the Progression
of Pancreatic Cancer invivo in KRAS and p53
pancreas- specific mutant mouse model
2.1 Study Design:
Forty two male KPC mice (KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ ) 6 to 8
weeks of age, were obtained from Van Andel Institute (Grand Rapids, MI ,USA). Mice
were housed individually under standardized protocol approved by Division of
Laboratory Animal Resources (DLAR), Wayne State University. Day and night cycle
was maintained with controlled temperature (25° C) and humidity. Food and water were
given adlibitum and 12hr dark and light cycle was maintained. Garcinol was purchased
from Enzo Life Sciences (Plymouth Meeting, PA), Garcinol containing diet (0.05%) and
the purified isocaloric diet were formulated and produced by Dyets Inc. (Bethlehem,
PA). Mice were weighed and acclimatized for one week. After acclimatization mice were
randomly assigned to four groups (Figure 2).
KC (n=8), KPC

mutant mice on control diet group were fed isocaloric diet

(Table-1) ( AIN 93G purified rodents diet, Dyets, Inc., Bethlehem, PA, USA) and
received intra-peritoneal saline injections (200 ul) from week 1 to week 5.
KGr (n=8) KPC mice on Garcinol diet mice were fed 0.05% Garcinol added
diet(Table-1) ( modified AIN 93G purified rodents diet, Dyets, Inc., Bethlehem, PA, USA)
and received intra-peritoneal saline injections (200 ul) from week 1 to week 5.
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KGm (n=8 ), KPC mice on control diet were fed isocaloric diet and received
intra-peritoneal Gemcitabine (100mg/kg in final volume 200 ul, LC laboratories, Woburn,
MA,USA) injections from week 1 to week 5.
KGG (n=8), KPC mice on Garcinol diet were fed 0.05% Garcinol diet and
received intra-peritoneal Gemcitabine (100mg/kg in final volume 200 ul) injections from
week 1 to week 5.
Littermates without mutations served as controls without cancer; these mice were
divided into two groups.
CC (n=5), Control mice on control diet, were fed isocaloric diet and received
intraperitoneal saline injections (200 ul) from week 1 to week 5.
CGr (n=5), Control mice on Garcinol diet were fed 0.05% Garcinol diet and
received intraperitoneal saline (200 ul) injections from week 1 to week 5.
Garcinol and isocaloric diet both had similar composition besides addition of
0.05% Garcinol in Garcinol diet (Table-1).

The dose of Garcinol was based on

previously reported dietary study without any toxicity and side effects [21]. As Garcinol
is a light sensitive compound all the precautions were taken during preparation and are
kept in dark bags after preparation. Small amount of diet sufficient for three to four days
was provided to the mice at one time.
Weight of the mice, their diet and water intake were monitored on a bi-weekly
basis. As KPC mice have tendency to develop very aggressive form of pancreatic
cancer (PaCa), 20 % weight loss or abdominal distention with respiratory distress were
set as criteria for early euthanization. Groups receiving gemcitabine were monitored for
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48 hours for toxicity symptoms of the dose including alertness, sudden weight loss and
loose stools.

0.05% Garcinol added Diet

Isocaloric Diet

Ingredient

kcal/g

grams/kg

kcal/kg

Ingredient

kcal/g

grams/kg

kcal/kg

Casein

3.58

200

716

Casein

3.58

200

716

L-Cystein

4

3

12

L-Cystein

4

3

12

Sucrose

4

100

400

Sucrose

4

100

400

Cornstarch

3.6

396.986

1429.1496

Cornstarch

3.6

397.486

1430.9496

Dextrose

3.8

132

501.6

Dextrose

3.8

132

501.6

Soybean Oil

9

70

630

Soybean Oil

9

70

630

t-Butyl

0

0.014

0

t-Butyl

0

0.014

0

0

50

0

Mix

0.88

35

30.8

Mix

3.87

10

38.7

0

2.5

0

1000.00

3760.0496

hydroquinone
Cellulose
Mineral

Mix

hydroquinone
0

50

0

Cellulose

0.88

35

30.8

Mineral

#210025
Vitamin

#210025
Mix

3.87

10

38.7

#310025
Choline

#310025
0

2.5

0

Bitartrate
Garcinol

Vitamin

Choline
Bitartrate

0

0.5

0

1000.00

3758.2496

Table 1- Composition of 0.05% Garcinol diet and isocaloric diet.
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Control KPC group (KC)
Standard diet/Saline
n=8

Experimental group
KPC mice

Garcinol group (KGr)
Garcinol diet/Saline
n=8

(KrasLSL.G12D/+; p53R172H/+;
PdxCretg/+ )

n=32

Gemcitabine Garcinol group
(KGG)
Garcinol diet/Gemcitabine
n=8

KPC Garcinol Study
n=42

Control group
Control mice
(Littermates without mutation)
n=10

Figure 2- Study design

Gemcitabine group (KGm)
Standard diet/Gemcitabine
n=8

Control group (CC)
Standard diet/Saline
n=5

Control Garcinol group (CG)
Garcinol diet/Saline
n=5
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To monitor tumor
progression with MRI
and Ultrasound.

Survival Data
Diet, weight
MRI
Scans

Evaluate possibility of toxicity
of dietary Garcinol by blood
smears , fore stomach and
pancreatic Hematoxylin and
Eosin slides (H&E).
Blood
Smear
slides
Fore
Stomach
H&E Slides
Pancreatic
H&E Slides

Figure 3: Specific aim 1-To investigate the invivo response of dietary Garcinol on
PaCa in mouse model.
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2.2 Methods:
Methods used for specific aim 1 are summarized in Figure 3 .

2.2.1 Magnetic Resonance Imaging (MRI):
MRI scans were conducted to monitor tumor growth in weeks 1 and 5 during the
study. Mice were weighed and were anesthetized with 80mg/kg body weight Ketamine
and 20mg/kg body weight Xylazine given intra-peritoneally and placed on heated
platform for scanning. Ophthalmic ointment was used to keep the eyes moist. Scans
were conducted on 7T scanner (ClinScan, Bruker, Karlsruhe, Germany). Overall
inflammation status and tumor volumes were measured during the scans. After the
scans, the mice were allowed to recover from anesthesia on the heated pads. A pallet
of food was provided inside the cage for easy access during recovery.

2.2.2 Plasma and tissue sample collection:
Mice were anesthetized with 100mg/kg Ketamine and 20mg/kg Xylazine. Mice
were euthanized at week 6 by exsanguination and removal of major organs.
Abdominal cavity was opened and blood was collected directly from the heart with
EDTA coated syringes and stored on ice in EDTA coated vials. Plasma was separated
by centrifuging at 3500 rpm for 15 minutes, measured and stored at -80°C for further
analysis. All the major organs were collected including Pancreas, liver, fore stomach,
spleen, kidneys, heart and testis. Tissue samples for histology were fixed in 10% neutral
buffered formalin.
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2.2.3 Blood smear slides preparation:
Blood (3 ul) was collected directly from the heart to avoid contact with EDTA.
This drop of blood was placed on the slide and smear was prepared by using a
spreader slide. Slides were dried at room temperature and then fixed in 95% ethanol for
one minute. Blood smears were stained by Wright Giemsa stain (Volu-Sol, Inc, Salt
Lake City, UT) according to the provided protocol. Briefly each slide was first immersed
into a jar of Wright-Giemsa staining solution for 30 seconds, then into a pH balanced
buffer for 60 seconds and finally in the rinse solution for 10 seconds. The blood smears
were observed for changes in the red and white blood cell morphology under the light
microscope NIKON ECLISPE (NIKON Instruments Inc, Melville, NY, after drying.

2.2.4 Histological evaluation of the formalin fixed pancreatic
tissue.
Pancreatic tissues collected at euthanization were fixed directly in 10% neutral
buffered formalin. After fixing, the samples were transferred to 70% ethanol to avoid
excessive drying of the tissue. The slides were stained with Hematoxylin and Eosin
(H&E) stain at the Histopathology lab, at Michigan State University. Briefly, samples
were vacuum infiltrated with paraffin on the Thermo Fisher Excelsior tissue processor;
followed by embedding with the Thermo Fisher Histo Centre III. After cooling, excess
paraffin was trimmed from the edges and the blocks were placed on a Reichert Jung
2030 rotary microtome. Blocks were faced to expose tissue sample, cooled and finely
sectioned at 4-5 microns. Sliced Sections were dried at 56°C slide incubator to ensure
adherence to the slides for 2 – 24 hours. Slides were removed from the incubator and
stained with Hematoxylin and Eosin stain. The procedure involved two changes of
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Xylene (5 minutes each), two changes of absolute ethanol (2 minutes each), two
changes of 95% ethanol (2 minutes each), running tap water rinse (2 minutes), Gill 2
Hematoxylin (ThermoFisher, Pittsburgh, PA) for 1 ½ minutes followed directly by a 10 –
15 second differentiation in 1% aqueous glacial acetic acid and running tap water for 2
minutes to enhance nuclear detail. Upon completion of running tap water slides were
placed in one change of 95% ethanol – 2 minutes, 1% Alcoholic Eosin-Phloxine B – 2
minutes to stain cytoplasm, one change of 95% ethanol for 2 minutes, four changes of
100% ethanol – 2 minutes each, four changes of Xylene – 2 minutes each followed by
cover-slipping with synthetic mounting . Slides were then observed under the light
microscope (Nikon Eclipse 80i).

2.2.5 Immuno-histostaining for S100P and DPC4:
To confirm the findings from the H&E slides immunohistochemistry was
conducted using S100P (Abcam #ab166649) and SMAD4/DPC4 (Abcam [EP618Y]
#ab40759) antibodies at the Histopathology lab (MSU, Lansing MI). The specimens
fixed and embedded in paraffin blocks earlier in H&E staining were sectioned on rotary
microtome at 4-5’s. These sections were then placed on slides coated with 2% 3 Aminopropyltriethoxysilane and dried at 56C overnight. The slides were deparaffinized
in Xylene and hydrated through ethyl alcohol to distilled water. Slides were then placed
in Tris Buffered Saline pH 7.4 (Scytek Labs – Logan, UT) for 5 minutes for pH
adjustment. Heat Induced Epitope Retrieval was performed utilizing Citrate Plus pH 6.0
buffer in a rice steamer for 30 minutes; followed by a 10 minute incubation at 25C
(Scytek).

Endogenous Peroxidase was blocked utilizing 3% Hydrogen Peroxide /

Methanol bath for 30 minutes followed by running tap and distilled water rinses.
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Following pretreatment standard avidin-biotin complex staining steps were performed at
room temperature on the DAKO Autostainer. All staining steps were followed by rinses
in Tris Buffered Saline + Tween 20 (Scytek). After blocking for nonspecific protein with
Normal Goat Serum (Vector Labs – Burlingame, CA) for 30 minutes; sections were
incubated with Avidin / Biotin blocking system for 15 minutes each (Avidin D – Vector
Labs / d-Biotin – St. Louis, MO).
S100P:
Primary antibody slides were incubated for 60 minutes with the Rabbit
Polyclonal anti – S100P diluted at 1:200 (Abcam – Cambridge, MA) in Normal Antibody
Diluent (NAD) (Scytek). Biotinylated Goat anti-Rabbit IgG (H + L) prepared at 11.0g/ml
in NAD incubated for 30 minutes (Vector); followed by R.T.U. Vectastain Elite ABC
Reagent incubation for 30 minutes (Vector). Reaction development utilized Vector Nova
Red peroxidase chromogen incubation of 15 minutes followed by counterstain in Gill 2
Hematoxylin (Thermo Fisher – Kalamazoo, MI) for 30 seconds then differentiation,
dehydration, clearing and mounting.
DPC4/SMAD4:
Primary antibody slides were incubated for 60 minutes with the Rabbit
Monoclonal anti – SMAD4/DPC4 diluted at 1:100 (Abcam – Cambridge, MA) in Normal
Antibody Diluent (NAD) (Scytek). Biotinylated Goat anti-Rabbit IgG (H + L) prepared at
11.0 g/ml in NAD incubated for 30 minutes (Vector); followed by R.T.U. Vectastain
Elite ABC Reagent incubation for 30 minutes (Vector). Reaction development utilized
Vector Nova Red peroxidase chromogen incubation of 15 minutes followed by
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counterstain in Gill 2 Hematoxylin (Thermo Fisher – Kalamazoo, MI) for 30 seconds
followed by differentiation, dehydration, clearing and mounting.

2.3 Statistical Analysis:
Analysis of variance (ANOVA) was conducted to evaluate the statistical
significance of the data using SPSS software (IBM SPSS Statistics, IBM Corporation,
Armonk NY). Significance level was set at p-value < 0.05, to be considered as
significant in reporting the results.
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2.4 Results and Discussion
2.4.1 Survival data, Body weights and diet intake:
All KPC mice in Garcinol fed group (KGr) survived the 6 week study period (100
percent survival). One mouse died due to complications of cancer in Cancer control
(KC) group, two mice each from Gemcitabine(KGm) and Gemcitabine Garcinol
group(KGG) were not able to complete the study(75% survival) either due to intestinal
obstruction or more than 20 % weight loss. All the non-mutant mice from control without
cancer groups (CC and CG) survived the study (Table 2). There was no significant
difference in average diet intake (p value > 0.05) or increase in body weights (p value >
0.05) from week one to week 6 in all the groups (Figure 4 & 5).
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Group Total Survived

%
Animal
Not
Survival
not
Survived
rate survived

CC

5

5

0

100%

CGr

5

5

0

100%

KC

8

7

1

87%

KGr

8

8

0

100%

KGm

8

6

2

75%

KC2

Remarks

KC2 died in Week 5 very weak

KGm3: Week 3 –Died (due to
KGm3 , intestinal & urinary obstruction)
KGm5 KGm5: Week 5-Sacrificed (very
weak & lost weight)

KGG

8

6

2

75%

KGG6: Week 5 -Sacrificed (very
KGG6 , weak & lost weight)
KGG8 KGG8: Week 6 -Died (due to
intestinal & urinary obstruction)

Table 2: Survival data KPC Garcinol Study.

Average Daily Diet intake(g)

25

4
3.5
3
2.5
2

1.5
1
0.5
0

CC

CGr

KC
KGr
Groups

KGm

KGG

Figure 4: Average daily diet intake during 6 weeks study in all groups. Error bars
represents ± mean standard deviation. No significant difference between the groups (p
value > 0.05).
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30
Week 1

Body weight (g)

25

Week 6

20
15
10
5
0

CC

CGr

KC

KGr

KGm

KGG

Groups
Figure 5- Average body weights compared week 1 to week 6 in all groups. Error
bars represents ± mean standard deviation. No significant difference was found from
week 1 to week 6 in all the groups (p value >0.05).
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2.4.2 Tumor Progression in KPC mice:
Tumors volumes in live animals were monitored using MRI (T2 weighted image
scans) and Ultrasound (20MHz transducer). Tumor progression was observed in KPC
mice on control diet without Garcinol or Gemcitabine treatment in KC group (Figure-6).
Ten tumors were monitored and seven of them grew in size from week 1 to week six in
KC group (Table-3).
Dietary Garcinol retarded the progression of Pancreatic Cancer in KPC mice. Of
the nine tumors monitored over 6 weeks’ time, only one grew in size, four of which
showed arrest in growth and four showed reduction in size (40% tumor reduction ). In
addition, there was a considerable reduction in inflammation of the peri-pancreatic area,
stomach and intestinal tract in the Garcinol fed mice group (KGr). Intestinal obstruction
due to inflammation and secondary tumors are common complications in KPC mice.
Reduction in swelling and abdominal distention was apparent from the MRI scans of
Garcinol fed mice from week one to week five (Figure-7).
Gemcitabine is a pyrimidine analog and works at two levels. It stops DNA
synthesis by incorporation in the elongating stand and it also targets Ribonucleotide
Reductase enzyme as it binds to the enzyme and inactivates it irreversibly. It is one of
the drugs of choice in pancreatic cancer treatment. The Gemcitabine group (KGm)
showed a mixed response to the drug, Figure 8 shows the MRI image from one mouse
that showed significant reduction in tumor volume and can be referred to as
Gemcitabine responder (10% response). Of the 10 tumors monitored and four of them
grew in size indicating that some mice did not respond to the Gemcitabine treatment
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(Table-3). Five tumors showed no difference in the tumor volume from week one to
week to week 6 (growth arrest).
The mice in the Gemcitabine plus Garcinol group (KGG) showed a better
response as compared to gemcitabine alone (Figure 9), 9 tumors were monitored and
two of them showed reduction in size with treatment and 6 showed arrest in growth.
One of the mice did not response to the treatment as indicated by the increase in tumor
size from week one to week 5 (Table-3). Some tumors were associated with cysts. It
was observed that Garcinol, Gemcitabine and Gemcitabine plus Garcinol groups
showed cyst volume reduction upon treatment in some mice (Table-3).
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A

B

C

D

Figure 6: Progression of Pancreatic cancer in KC group.
A, KC transverse view week 1. B, KC transverse view week 5. C, KC coronal view
week1. KC coronal view week 5.
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A

C

B

D

Figure 7: Reduction of tumor volume and inflammation in KGr group.
A, KGr transverse view week1. B, KGr transverse view week 5. C, KGr coronal view
week 1. D, coronal view week 5
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A

C

B

D

Figure 8: Gemcitabine responder and Non Responder.
Gemcitabine Responder- A, coronal view week 1 & B, week 5 and Gemcitabine nonresponder C, week 1 & D, week 5.
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A

B

Figure 9: Garcinol and Gemcitabine combination (GG) showed reduction in tumor
and Cyst.
A, KGG coronal view week 1. B, KGG coronal view week 5.

33

Group

Total
Number of
Tumors
monitored

Number
of tumors
increased
in size

Number
of tumors
decreased
in size

Total
Number
of
Cysts
monitored

Number
of cysts
increased
in size

Number
of cysts
decreased
in size

KC

10

7

-

4

4

-

KGR

9

1

4

3

2

1

KGM

10

4

1

5

3

2

KGG

9

1

2

6

3

3

Table 3: Tumors and Cysts monitored by MRI in KPC mice.

2.4.3 Investigation of Fore- stomach H& E slides for possible
toxicity of Dietary Garcinol:
As Garcinol was administered through diet, we investigated the fore- stomach
H&E slides for possible toxicity of dietary Garcinol. Fore stomach the proximal third part
of the stomach is non- glandular and has keratinized stratified squamous epithelium.
The latter two third glandular part of the stomach has cap cells chief cells and parietal
cells for gastric secretions [34]. Epithelial lining gets irritated and hypertrophied with
ingestion of toxic substances. Fore stomach epithelium, mainly mucosal epithelium gets
hypertrophied with repeated doses of toxic compounds. Sometimes this is associated
with keratosis and inflammation and can leads to severe complications if not addressed
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at earlier stages [35]. Along with chemical irritant , insecticides and drugs, some
synthetic and naturally occurring anti-oxidants have shown fore stomach hyperplasia
and toxic effects after oral administrations as early as four weeks[36].
As shown in Figure 10, we observed no toxicity of Garcinol to the fore stomach
after oral administration for six weeks in control mice on Garcinol diet group (CG). The
fore stomach lining was comparable to control mice on control diet group (CC) after
dietary Garcinol ingestion for 6 weeks. This indicates that Garcinol ingestion does not
cause any hyperplasia of fore-stomach lining mucosa.
Upon investigation of the fore- stomach from KPC mice ( KC), a lot of
inflammation, papilloma formation and hyperplasia of most of the fore stomach lining,
consistent with the phenotype of these mice with stomach and intestinal obstruction,
inflammation and swelling was observed. These papillomas were more evident near
the junction of fore-stomach and glandular stomach (Figure- 10), referred to as squamocolumnar or fore-stomach/zymogenic junction in previous studies [34]. The histology
and pathology was quite similar to the mataplastic, columnar and glandular gastric
tumors reported earlier in a study with SMAD 3 zinc deficient mice [37]. Similar tumors
were also reported in p53 null and zinc deficient mice with N-nitrosomethylbenzylamine
(NMBA) administration [38]. Fore stomach in rodents is considered as a dilation of the
esophagus and is comparable to human esophageal /stomach junction. This portion of
stomach is more sensitive than the esophagus in mice, although both are lined by
squamous epithelium [38].
Interestingly Garcinol fed KPC mice showed marked reduction in these
papillomas. Even more fascinating was the fact that the stomach lining of some Garcinol
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fed mice were comparable to the non-cancer groups (CC and CG) (Figure-3). This
finding correlated with our MRI results where we observed reduction in inflammation
and swelling of the intestinal tract specially stomach and duodenum with Garcinol
administration. Intestinal obstruction is a major cause of weight loss and death in KPC
mice. All the Garcinol fed mice (KGr) mice survived the study and didn’t show any signs
of these complications. This may be attributed to its protective effect on the stomach
lining.
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Figure 10 : Fore-Stomach H&E slides showed no toxicity to Dietary Garcinol
• Mice without cancer on control diet (CC)
– (A): normal fore-stomach lining epithelium in (B): Normal
Squamo/columnar junction in CC
• Mice without cancer on Garcinol diet (CGr)
– (C): no sign of hypertrophy or toxicity
• KPC mice on control diet (KC)
– D, Papilloma formations ; E, Squamo-columnar junction with papilloma like
changes; F, Inflammation
• KPC mice on Garcinol diet (KGr)
– G, H & I, normal fore-stomach lining and less papilloma like changes.
Squamo-columnar junction in KGr group similar to CC group.
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2.4.4 Investigation of Blood smears for possible toxicity and
immune response in KPC mice:
Blood smears prepared at the end of the study, were stained with Wright and
Giemsa stain and observed under light microscope (Nikon Eclipse), to explore the
effects of dietary Garcinol on blood morphology and rule out possible toxicity. Changes
in red blood cell following exposure to toxics/drugs are common. These include
basophilic stippling with metal poisoning, bite cells and Heinz bodies in oxidative stress
and blister cells in aromatic drugs exposure. No changes to red blood cells post
Garcinol administration were observed in any of the Garcinol fed animals indicating that
0.05% dietary Garcinol did not cause any toxic effects on red blood cell of KPC or
control (non-mutant) mice.
Total white blood cell count showed no significant differences in the experimental
groups as compared to control group. However, while counting total lymphocytes it was
noticed that there were more number of Large granular lymphocytes LGLs.(Figure 11,
mainly Natural killer cells (NK cells) and Natural killer T cells (NKT cells), in the Garcinol
fed group blood smears as compared to other KPC groups. NK cells are the first line of
defense against tumor cells and represent the innate immune response [39]. NK and
Natural kill T cells (NKT) have similar phenotype and function in response to tumor
cells [40]. In order to investigate the innate immune response to pancreatic cancer in all
the groups, we measured the number of the NK & NKT cells and compared it with the
number of non NK lymphocytes in all the groups of mice (Figure- 12).
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Figure 11: Large granular lymphocytes (NK & NKT)- In Garcinol fed group(Wright
Giemsa stain), NK &NKT cells are larger in size and have granular, irregular nucleus.
Non NK lymphocytes have round heterochromatic nucleus with thin rim of Cytoplasmic.
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Large granular lymphocytes (LGL) have granules and an irregular-shaped
nucleus. These are larger in size than other lymphocytes. Non NK Lymphocytes
generally have a round, heterochromatic nucleus with thin rim of cytoplasm around it;
they are much smaller in size compared to LGLs.
Interestingly the NK & NKT cells number compared to non NK lymphocytes was
significantly high in Garcinol treated group (KGr) as compared to other groups with p
value<0.001 (Figure - 12). Increase in NK & NKT cells can be a very valuable finding
and warrants further investigation. A follow up study, measuring population of these
cells by flow cytometry at different time points with Garcinol administration may be
useful in understanding the mechanism of this effect.
The role of NK & NKT cells against tumor cells has been investigated in many
studies including carcinogen induced and transgenic mouse models. NK &NKT cell can
be helpful in cancer therapy in many ways. NK cells can target tumor cells through
multiple pathways including release of perforins and granzymes, death receptor
activation and gamma interferon and nitric oxide pathway [41]. NKT cells can also target
tumor cells, by directly killing tumor cells or indirectly by activation of NK cells at early
stages of cancer development by mechanisms that may or may not require antibody
response. In addition invariant NKT ( iNKT) cells can regulate production of angiogenic
factors by tumor associated macrophages containing CD1d and can therefore have
repressive effect on angiogenesis[40]. Recent studies have suggested use of NKT
cultured cells supplementation along with CD1d antibodies as cancer therapy [40]. NK
and NKT cells secrete cytokines like interferon-γ (IFNγ) that participate in adaptive
immune response [40]. Adjuvant therapy with agents inhibiting formation of reactive
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oxygen species like Histamine can assist in NK cell immunotherapy to overcome
challenges produced by infiltrating monocytes and macrophages[42].

90

b
NonNK

a
80

Percentage lymphocytes

NK&NKT
70

60

50

40

30

20

10

0

CC

KC

CG

KGr

KGm

KGG

Groups
Figure 12: Change in lymphocyte population with dietary Garcinol. Percentages of
NK and NKT compared to Non NK lymphocytes, KGr group ( Garcinol fed) showed
significantly high percentage of NK & NKT cells (‘a‘ is significantly different from ‘b’
pvalue<0.001), almost reversal of the ratio as observed in other groups. Error bars
represents standard error of mean.
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2.4.5 Histological investigation of pancreatic tissue:
KPC mice develop a wide range of changes in the pancreas comparable to
changes that occurs during progression of ductal adenocarcinoma in humans. These
changes include genetic instability, increased nuclear cytoplasmic ratio, loss of acinar
tissue organization, nuclear pleomorphism and loss of cell differentiation [32].These
mice shows premalignant Pancreatic intraepithelial neoplasia similar to those in human
disease. These lesions usually contain mucin and are cytokeratin 19 positive [32]. They
have 100% penetrance with a variable latency period along with an average median
survival of four and half months.
In order to investigate the pancreatic lesions in our mice we used the criteria
established by the International workshop held in University of Pennsylvania, cosponsored by National Cancer Institute in 2004 [31]. One of the goals of this work shop
was to evaluate different models of Pancreatic exocrine neoplasia and set uniform
criteria to describe pathology of these genetically engineered mice so it will enable the
comparison with human disease [31].
There are architectural and cytologic changes which need to be observed for indepth evaluation of pancreatic lesions. Architectural changes includes the formation of
abnormal structures like masses and cysts, changes in the location of structures and
transformation of tissue, invasion and of new cells to the tissue which does not belong
to the area. Cytological changes include cellular hypertrophy, atrophy, metaplasia,
hyperplasia, apoptosis and cell necrosis. In addition changes of the interstitial tissues
including fibrosis, desmoplasia and inflammation should also be noted in complete
investigation of the tissue.
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Pancreatic lesions; those meeting specific criteria, including ductal proliferation
should be within native pancreatic duct, involved duct should measure less than 1mm
and should be differentiated from acinar ductal metaplasia were classified as mouse
Pancreatic intraepithelial neoplasia (mPanIN). The word mouse was added as these
lesions were similar to human pancreatic intraepithelial neoplasia but they all progress
to invasive ductal adenocarcinoma in mice [31].
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A

B

C

D

Figure 13: mPancreatic Intraepithelial Neoplasia (mPanIN).
A, Normal pancreatic tissue. B, PanIN-1. C, PanIN-2. D, PanIN-3.
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Grading of mPanIN was based on architectural and cytological changes, starting
with normal pancreatic ductal epithelium which is cuboidal to low columnar with
amphophilic cytoplasm with no atypia. mPanIN-1a has tall columnar cells with basally
located round to oval nuclei and large amount of mucin (Figure-13). They also may
have papillary or micropapillary with a single layer of nuclei (mPanIN 1b). mPanIN-2
contains mostly papillary structures but may be flat. These some cytological changes
like loss of polarity, nuclear crowding, enlarged nuclei and hyperchromatism (Figure-13
C). mPanIN 3 are papillary and micropapillary lesions. Budding of clusters of epithelial
cells into the lumen with luminal necrosis (Figure-13 D). Cells show loss of polarity,
abnormal mitosis and goblet cells. These lesions have all the characteristics of invasive
carcinoma but the basal membrane is not breached.
Invasive pancreatic ductal adenocarcinoma (PDA) can be well or poorly
differentiated. It is defined as malignant epithelial neoplasm with ductal differentiation
that has penetrated through the ductal basement membrane [31]. In KPC mouse model
PDA is mostly undifferentiated carcinoma which is invasive neoplasm with no glandular,
acinar, endocrine or squamous differentiation. Loss of lobular normal pancreatic
architecture is also evident in these lesions [31].
KPC mice showed all stages of mPanIN along with invasive Pancreatic ductal
adenocarcinoma (PDA). Full array of architectural, cytological and interstitial changes
was observed validating the clinical relevance of this mouse model. PDA lesions were
associated with cyst formation in number of cases. Acinar ductal metaplasia was
prevalent in the almost all of the mice included in the study. Most of the mice showed
untouched endocrine with slight compensatory hyperplasia in cases where fibrosis has
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damaged lobular structure of the pancreas. Acute and chronic inflammations leading to
formation of granuloma like aggregates were observed. Fibrosis and desmoplsia were
widespread in the mice with PDA. In addition to peri-pancreatic lymph nodes, intrapancreatic lymphoid tissue aggregates with sinus histocytosis were also observed with
advanced PDA lesions.
Overall the total number of mPanINs were decreased in KGr, KGm and KGG
groups with lowest number observed in the KGG group (p = 0.005). Highest numbers of
mPanIN3s were observed in KC group and lowest number in KGG group (p =0.002).
This indicates slower progression of mPanIN lesions from mPanIN1 to mPanIN 3 in the
Garcinol fed groups as compared to KC group (Figure-14).
According to histology we saw improvement in three gemcitabine treated mice,
slow responders although in MRI we saw only one clear Gemcitabine responder based
on tumor volumes. KGG group showed well preserved lobular structure, ductal, acinar
and endocrine pancreas among all groups (Figure- 14).
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a
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Number of PanIN
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8

mPanIN1

6

mPanIN2

b
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b

mPanIN3
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KC

KGR
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Figure 14: Comparison of mPanIN numbers and stages in different groups.
(‘a‘ is significantly different from ‘b’)
KC group had highest number total number of mPanIN (p value < 0.05) and KGG had
lowest number of mPanIN (p value< 0.05). Reduction of mPanIN 2 and 3 was observed
with Garcinol and Gemcitabine treatment (p value < 0.05). KGG had lowest number of
mPanIN 3 (p value < 0.05).
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2.4.6 Immunohistochemistry with S100p and DPC4 antibodies:
S100p is a member of s100 family of proteins and is not usually expressed in
pancreas. However it is reported to be expressed in pancreatic cancer [43]. This is
primarily due to hypo-methylation of the gene as reported in earlier studies.
Overexpression of s100p normally correlates with resistance to chemotherapy and
increased metastatic potential [43]. S100p provided support to cancer cell proliferation
leading to pancreatic cancer cell survival [43]. This protein interacts with the RAGE
receptor which in turn activates different cell signaling pathways including MAP kinase
and Fib, causing increased survival, growth and metastasis of tumor cells. S100p also
takes part in degradation of β catenin through interaction with Cacy/SIP, a component of
the ubiquitination pathway. It has been reported that s100p is a good marker for Pan IN
progression and there is a considerable increase in expression from PanIN 1 (13%
expression) to PanIN2 (31% expression) and PanIN3 (41% expression) [44]. Lesions
positive for S100P have been reported to be significantly related to progression into
invasive ductal adenocarcinoma [44]. Expression of S100P was shown to be very
effective in diagnosis of Pancreatic ductal adenocarcinoma (PDA). In a study conducted
on fine needle biopsy samples from patients with different pancreatic tumors, S100P
immunostaining was found to be positive for all PDA samples. The immunoreactivity
was reported negative for all endocrine tumors and only one benign sample was found
positive [45]. In another study S100P was shown to be one of the best immunomarker
of ductal adenocarcinoma of pancreas along with pVHL, maspin, and IMP-3 [46]
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Immunohistochemistry with S100P antibody showed that these mPanIN lesions
in KPC mice are positive to S100P. Upon detailed examination of the slides, expression
of S100P increases with progression of mPanIN and was highest in PDA. KC group
showed very strong staining (Figure 15) in mPanINs confirming our findings from H& E
slides that the KC group had the highest number of advanced mPanINs and PDA.
Lymphoid tissue from KC mice showed S100P labeling in lymph node with stained cells
in the center of lymph node. S100P stained cells were also observed on ducts and
blood vessels (Figure 16). KGr group showed much cleaner S100P stained slides, with
few mPanIN lesions stained for S100P (Figure 17). Lymphoid tissue also have very few
s100P positive cells, if present they were in the periphery of the lymph nodes (Figure
18). KGm mice showed less S100P staining in the responders and more expression in
the non-responders consistent with H&E findings (Figure 19). KGG group confirmed to
be the best response group to the treatments with least expression of S100P
(Figure20). S100P staining is not reported in KPC mice before. Expression of S100P
can be very useful predictor of progression of PDA in this clinically relevant mouse
model of pancreatic cancer.
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Figure 15: higher expression of S100P in PanIN and PDA in KC group (KPC on
control diet).
Three different sections from KC group showing advanced pancreatic lesions with high
S100P staining.
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Figure 16: Peri-pancreatic lymph node in KC mice, showed many S100P positive
cells in the center of lymph node.
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Figure 17: KGr group (KPC Garcinol fed) showed lower expression of S100P
compared to KC group.
Three different sections from KGr group showing less S100P staining compared to KC
group.
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Figure 18: Lymph node in KGr group with very less S100P staining.
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Figure 19: S100P staining in KGm group. KGm group (KPC Gemcitabine treated)
showing less staining and fibrotic tissue in responder and more S100P staining in nonresponders
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Figure 20: S100P staining in KGG group-showing more consistent lower expression
of S100P in KGG group (KPC Gemcitabine plus Garcinol)among all the groups.
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Deleted in pancreatic cancer (DPC4)/ Mothers against decapentaplegic homolog
4 (SMAD4) is a tumor suppressor gene normally inactivated in pancreatic cancer. It
usually occurs by heterozygous deletion and mutation in other allele or by homozygous
deletion of the gene during progression of the disease [47]. Inactivation of is DPC4 is
specific to pancreatic cancer and it occurs mostly late in PanIN3 stage. Loss of DPC4
can be predictive of invasive properties of the PanIN lesions [48]. Although there was
not much difference in the pathology and characteristics of pancreatic tumors, DPC4
positive Pancreatic cancer patients have shown longer survival trend in clinical
setting[47]. We have p53 and K-ras conditional mutations in KPC mouse model, in
order to investigate whether DPC4 is also affected during the development and
progression of pancreatic lesions in this model, we explored paraffin fixed pancreatic
tissue with DPC4/SMAD4 antibody. KPC mice without any treatment (KC) showed loss
of DPC4 labeling with antibody in advanced mPanINs and PDA. Additionally there were
areas with generalized fading in normal structures of pancreas in some KC mice
indicating that loss of DPC4 can come as an earlier event in some cases before the
area gets aggressive PDA lesion (Figure 21). KGr group overall showed higher
expression of DPC4 correlating with H&E findings with less mPanIN lesions and
preserved lobular structure, ducts and endocrine regions (Figure 22). There were some
areas of advanced mPanINs and PDA that showed loss of DPC4 indicating that loss of
DPC4 due to advancement of the disease, leading to genetic instability. KGm showed
mixed response as some of them showed diffuse labeling with DPC4 antibody but some
of them were generally faded most of the pancreatic tissue (Figure 23). Interestingly one
of the responders to Gemcitabine showed over all fading with very little area of normal
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DPC4 staining where as one of the non-responder has more ducts with DPC4 labeling.
Garcinol plus Gemcitabine treatment in KGG groups showed the most staining and well
preserved DPC4 expression representing preservation of normal morphology of most of
the pancreas in this group, consistent with our previous H&E and S100P observations
(Figure 24).
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Figure 21: DPC4 Staining in KC Group. A&B, Very less DPC4 staining in KC
group(KPC on control diet ) with progression of PanIN and PDA.C, lymphoid tissue in
KC group showed almost no DPC4 positive cells
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Figure 22: DPC4 staining in KGr group- A&B KGr group (KPC Garcinol fed) Showed
preserved DPC4 in pancreatic tissue. C, Lymphoid tissue in KGr group with DPC4
staining.
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Figure 23: DPC4 Staining in KGm group- A, DPC4 positive Gemcitabine
responder. B& C, Less staining in Gemcitabine non-responders.
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Figure 24: DPC4 Staining in KGG Group- A, B & C Higher expression of DPC4
in KGG group(KPC Gemcitabine plus Garcinol).
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CHAPTER 3: Epigenetic Modulation of Tumor
Promoter Genes Through microRNAs in Garcinol fed
Transgenic Pancreatic Cancer Mouse Model
MicroRNA are small ~20 nucleotide long, noncoding RNAs which have the
potential of silencing mRNAs for specific genes. Although the exact mechanism of gene
silencing is under investigation, 3’ UTR of mRNA and first 8 nucleotides of miRNA play
important roles. One mRNA can be repressed by multiple miRNAs [49, 50]. Although
there is little complementation between 3’UTR and seed region (2-8 nt in 5’region) of
miRNA, it is sufficient to cause repression of mRNA and sometimes leads to
degradation of mRNA itself. If there are multiple target sites of lesser complementarity,
these can lead to Ribonuclear protein (RNP formation) which leads to translational
inhibition but can spare degradation of mRNA.

Some of the genes have single

predicted target site but mostly target genes have multiple sites which leads to
cooperative binding [51]. The level of suppression also depends on the availability of the
mRNA and miRNAs and they compete for binding. Although miRNA genes comprise
only one percent of our human genome, they can affect up to ten percent of the total
protein production [51]. These small RNAs can be responsible for major alterations in
key metabolic pathways through their target genes[52].
Pancreatic cancer has a very complex stroma and miRNAs can cause alterations
to this microenvironment. Additionally Pancreatic tumors are glucose dependent and
some miRNA target genes are involved in major glucose metabolic pathways. Metabolic
pathways can regulate production of some miRNAs and alternatively some miRNAs are
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responsible for changes in metabolism in pancreatic cancer. Based on some research
studies

specific miRNA can differentiate among normal Pancreas and Pancreatic

Cancer [52]. Reactive oxygen species (ROS), hypoxia, glucose status and major tumor
related genes alter different sets of miRNA including up regulation of miR23a/b,
miR155, miR125, miR21, miR181b, miR210, miR212, miR409 and miR 132 in
Pancreatic cancer [52]. Pancreatic Cancer and other pancreatic diseases like chronic
pancreatitis have miRNA signatures which can differentiate them from normal pancreas.
These miRNA signatures have potential to identify long term and short term survivors
[53].
Recently several studies s have shown potential of natural bioactive food
components in modulation of miRNA profiles leading to suppression of tumor promotor
miRNAs and up regulation of tumor suppressor miRNAs. Agents investigated includes
curcumin , isoflavones, resveratrol, Indoles, catechins and Ellagitannin [54].
Garcinol has modulated miRNA profiles in positive manner, invitro studies in our
lab. Oncogenic miRNA 21, 196a and 495 were down regulated and miRNA 638 and
453 tumor suppressor miRNA were up regulated (in a pancreatic cancer cell line when
treated with Garcinol). In this study we investigated miRNA profile and some of the
target genes to study the effects of Garcinol invivo.

3.1 Methods:
3.1.1 RNA Extraction:
Total RNA extraction was performed with a RNeasy Mini Kit ( Qiagen Valencia,
CA, USA) according to the manufacturer’s instructions. Briefly, first, an approximate
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weight of 30mg of frozen liver and pancreatic tissues were excised and placed into 700
uL QIAzol Lysis Reagent for disruption and homogenization using tissue homogenizer
until sample was uniformly homogenous. Tube containing homogenate was then placed
at room temperature (15-25˚C) for 5 minutes. 140 uL of chloroform was then added and
tube was capped securely followed by vigorous shaking for 15 seconds. The tube was
then placed at room temperature for 3 minutes prior to centrifugation for 15 minutes at
12,000 rcf at 4˚C. Following centrifugation, the upper aqueous phase was transferred to
a new collection tube. 525 uL of 100% ethanol was added and mixed thoroughly by
pipetting. Next, 700 uL of sample including any precipitate was pipetted into RNeasy
Mini spin column in 2 ml collection tube and centrifuged at 10,000 rpm for 15 seconds.
The flow-through was discarded and this step was repeated with remainder of sample.
700 uL of Buffer RWT was then added to RNeasy Mini spin column, centrifuged at
10,000 rpm for 15 seconds and flow-through was discarded. 500 uL of Buffer RPE was
then pipetted onto RNeasy Mini spin column and again and centrifuged at 10,000 rpm
for 15 seconds. The flow-through was discarded and another 500 uL of Buffer RPE was
added to RNeasy Mini column, centrifuged at 10,000 rpm for 2 minutes. RNeasy Mini
spin column was then places into a new 2 ml collection tube and centrifuged at full
speed for 1 minute. The collection tube was discarded with the flow through. Finally,
the RNeasy Mini spin column was transferred to a new 1.5 ml collection tube, 40uL of
RNase-free water was pipetted directly on the RNeasy Mini spin column membrane and
centrifuged for 1 minute at 10,000 rpm to elute the RNA. Quantity measurement and
spectrophotometric quality assessment (A260/280 and A260/230 ratios) of RNA were then
carried out using the Nanodrop spectrophotometer.
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3.1.2 CDNA Preparation:
Reverse transcription for pancreatic RNA was performed using miScript II RT Kit
(Qiagen GmbH, Hilden, Germany). The reverse transcription master mix consisted of 4
uL 5x miScript HiFlex Buffer, 2 uL miScript Nucleic Mix, 2 uL miScript Reverse
Transcriptase Mix and 4 uL RNase-free water prepared in 0.2 mL PCR tube, gently
mixed and stored on ice. Next, 8 uL template RNA (equal concentrations of 1000 ng/ul
for all samples) was added to each tube containing reverse transcription master mix,
gently mixed and briefly centrifuged. These tubes were then loaded into Eppendorf
mastercycler realplex 4 (Eppendorf, Hauppauge, NY) for reverse transcription process,
incubated at the following temperatures; 37˚C for 60 minutes, 95˚C for 5 minutes and
kept at 4˚C until retrieve for immediate use for qRT-PCR analysis or transferred to a 20˚C freezer.
Reverse transcription for liver RNA was performed using High Capacity RNA to
cDNA Master Mix kit (Applied Biosystems, Carlsbad, CA). Briefly, 20 uL of RT buffer
mix, 2 uL of RT enzyme mix, 8 uL of RNA sample (equal concentrations of 1000 ng/ul
for all samples) and 10 uL of nuclease-free water were mixed into 0.2 mL PCR tube and
centrifuged for few seconds. Prepared samples were then

loaded into Eppendorf

mastercycler realplex 4 (Eppendorf, Hauppauge, NY) for reverse transcription process
with the following temperature setting; 25˚C for 5 minutes, 42˚C for 30 minutes, 85˚C for
5 minutes and kept at 4˚C until retrieve for immediate use for qRT-PCR analysis or
transferred to a -20˚C freezer.
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3.1.3 MicroRNA microarray:
Microarray analyses were performed at LC Sciences (Houston, TX). Briefly, total
RNA was extracted as described above, RNA integrity was determined and all the
samples were subjected to Quality control Analysis(QC). After QC RNA samples were
enriched for micro RNAs, enriched samples were then labeled with fluorescent dye
(C5). Hybridization was performed overnight on a µParaflo microfluidic chip probed with
a chemically modified nucleotide coding segment complementary to miRNA transcripts
listed in Sanger miRBase.
Multiple quality control steps were incorporated to various stages of assay
including multiple sets of control probes were distributed throughout the array. Data
normalization was achieved by using cyclic LOWESS (locally weighted regression)
method to remove system related variations in the data. ANOVA was performed on
signal intensities to evaluate significance of data.
Normalized data was also subjected to Principle component (PCA) multi-variate
analysis using SIMCA P+ (Umetrics, San Jose, CA).

3.1.4 Quantitative Real-Time Polymerase Chain Reaction (qPCR)
for miRNA expression:
cDNA prepared from pancreatic tissue samples using miScript HiFlex Buffer
served as the template for real-time PCR using an miRNA-specific miScript Primer
Assay and the miScript SYBR Green PCR Kit (Qiagen, Venlo, Netherlands & Hilden,
Germany). Based on microRNA microarray analysis two miRNA mmu-miR- 451a and
mmu-miR-23a for PCR validation. Briefly, final reaction volume of 25 uL consisted of
12.5 uL 2x QuantiTect SYBR Green PCR Master Mix, 2.5 uL of 10x miScript Universal
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Primer, 2.5 uL 10x miScript Primer Assay, 5.5 uL of RNase-free water and 2 uL of
cDNA (equal concentrations of 10ng/ul for all samples). qRT-PCR was carried out on
the Eppendorf mastercycler realplex 4 instrument (Eppendorf, Hauppauge, NY) in
Mx3000P 96-Well Plates (Agilent Technologies) with the following program; initial
denaturing: 95˚C for 15 minutes, 40 repeats of denaturing: 94˚C
annealing: 55 ˚C (30 seconds) and extension : 70˚C

(15 seconds),

(30 seconds). Each miRNA

sample was analyzed in triplicate with single NTC. miRNA expression levels in the
samples were calculated relative to KPC control (KC) using the comparative C T method:
∆∆CT = ∆CT sample - ∆CT control, fold change = 2-∆∆CT. Small nuclear RNA, snRNA
RNU6B (RNU6-2) was used as PCR control and to normalize the expression values
(∆CT).

3.1.5 Quantitative Real-Time Polymerase Chain Reaction (qPCR)
for mRNA expression:
Some of the target genes expressions were investigated using RTPCR .

In

pancreatic tissue we selected Cyclin D1 from cell cycle, MMP9 from metastasis and
invasion pathway, BCL2 and Notch 1 from apoptosis and tumor progression. Three
genes were tested in common metastasis site in liver, CyclinD1, MMP9 and BCL2. The
primer sequence of these genes are listed in Table 4. The final reaction volume of 25
uL consisted of 12.5 uL SYBR Green PCR Master Mix (Applied Biosystems,
Warrington, UK), 1 uL of 20 uM reverse and forward primer mixture, 9.5 uL nucleasefree water and 2 uL of cDNA (equal concentrations of 10ng/ul for all samples). qRTPCR was carried out on the Eppendorf mastercycler realplex 4 instrument (Eppendorf,
Hauppauge, NY) in Mx3000P 96-Well Plates (Agilent Technologies) with the following
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program; initial denaturing: 95˚C for 10 minutes, 45 repeats of denaturing: 95˚C (15
seconds) and elongation: 60˚C (1 minute), dissociation curve: 95˚C for 1 minute, 60˚C
for 30 seconds followed by gradual temperature increase from 60˚C to 95˚C
minutes and finally at 95˚C

in 20

for 30 seconds. Each group was represented by n=4

samples in pancreas and n=5 samples in liver. Each gene was analyzed in triplicate
with single NTC for each sample. mRNA expression levels in the samples were
calculated relative to control, isocaloric diet-no chemotherapy group (KC) using the
comparative CT method: ∆∆CT = ∆CT sample - ∆CT control, fold change = 2-∆∆CT βactin was used to normalized the expression values (∆CT).
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Primer’s
Name

Forward Sequence

Reverse Sequence

COX 2

5’-GTCCCTCACCCTCCCAAAAG-3’

5’-GCTGCCTCAACACCTCAACCC-3’

BCl2

5’-CCTGTGGATGACTGAGTACC-3’

5’-GAGACAGCCAGGAGAAATCA-3’

CyclinD1

5’CCTCCAGAGGGCTGTCGGCGCAGTAGCAGA-3

5’-TCTTACCTCCAGCATCCAGGTGGCCACGAT-3’

MMP9

5’- GCTCCTGGTCTCCTGGCTT-3’

5’-GTCCCACTTGAGGCCTTTGA-3’

β-Actin

5′-ACCAACTGGGACGACATGGAGAAG-3′

5′-TACGACCAGAGGCATACAGGGACT-3′

NOTCH1

5’-ATTGAAAGCACATATGGAGAT-3’

5’-GTATAAGCATGAAGTGGTCCA-3’

Table 4: Primer sequences used for RTPCR .
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3.2 Results and Discussion:
3.2.1 MircoRNA microarray:
Number of MicroRNA in the Garcinol treated group were found to be significantly
differently expressed in the microarray data (p value ≤ 0.05) as compared to non-treated
KC group (Figure 25) . Most of the miRNA were up or down regulated in the favorable
manner based on previous research studies in the field. Many of miRNAs modulated
were related to cancer

and some of them

were found to be directly related to

Pancreatic Cancer after search through different databases like miR Base (Manchester,
UK) miR2Disease Base( Harbin institute of technology, School Of

edicine, Indiana

University) , miRCancer (microRNA Cancer association database) and IPA (Ingenuity
Systems Inc, Redwood City, CA).
Table 5 lists miRNAs differently expressed in treated KPC mice groups(KGr,
KGm and KGG) compared to untreated group KC ( p value ≤ 0.05). The table also
includes seed regions of the miRNA, up or down regulation with Garcinol treatment and
their relation to cancer, and pancreatic cancer.
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Figure 25: Heat maps and Hierarchical Clustering of miRNA microarray statistical
significance < 0.01.
A, represents miRNA differently expressed with statistical significance <0.001. B,
represents miRNA differently expressed with statistical significance < 0.05 and C,
represents miRNA differently expressed statistical significance <0.1.
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MicroRNA

Seed region

Garcinol PaCa
treated
link

Cancer
link

mmu-miR-23a-3p

AUCACAUUGCCAGGGAUUUCC

↓

Yes ↑

Yes↑

mmu-miR-27b-3p

UUCACAGUGGCUAAGUUCUGC

↓

UNK

Yes↑

mmu-miR-214-3p

ACAGCAGGCACAGACAGGCAGU

↓

Yes ↑

Yes↑↓

mmu-miR-99b-5p

CACCCGUAGAACCGACCUUGCG

↓

Yes ↑↓

Yes↓

mmu-miR-23b-3p

AUCACAUUGCCAGGGAUUACC

↓

Yes ↑

Yes↑↓

mmu-miR-451a

AAACCGUUACCAUUACUGAGUU

↑

Yes ↑↓

Yes ↓

mmu-miR-125b-5p

UCCCUGAGACCCUAACUUGUGA

↓

Yes ↑

Yes↑↓

mmu-miR-125a-5p

UCCCUGAGACCCUUUAACCUGUGA

↓

Yes ↑

Yes ↓

Low signals but Statistically significant p≤0.05
mmu-miR-5132-5p

GCGUGGGGUGGUGGACUCAGG

↑

UNK

UNK

mmu-miR-6368

CUGGGAAGCAGUGGAGGGGAG

↑

UNK

UNK

mmu-miR-127-3p

UCGGAUCCGUCUGAGCUUGGCU

↓

Yes

Yes ↓

mmu-miR-504-3p

AGGGAGAGCAGGGCAGGGUUUC

↑

UNK

UNK

mmu-miR-328-3p

CUGGCCCUCUCUGCCCUUCCGU

↓

UNK

Yes↑↓

mmu-miR-193a-3p

AACUGGCCUACAAAGUCCCAGU

↑

UNK

Yes↑↓

mmu-miR-667-5p

CGGUGCUGGUGGAGCAGUGAGCACG

↓

UNK

UNK

mmu-miR-224-5p

UAAGUCACUAGUGGUUCCGUU

↓

Yes

Yes ↑

mmu-miR-466m-3p

UACAUACACACAUACACACGCA

↑

UNK

Yes ↑

mmu-miR-327

ACUUGAGGGGCAUGAGGAU

↑

UNK

Yes

mmu-miR-5620-5p

ACGAGGCAGGGGCUUUGACUGUG

↑↓

UNK

UNK

mmu-miR-183-5p

UAUGGCACUGGUAGAAUUCACU

↓

Yes ↑

Yes↑↓

mmu-miR-3100-5p

UUGGGAACGGGGUGUCUUUGGGA

↑

UNK

UNK

mmu-miR-193a-5p

UGGGUCUUUGCGGGCAAGAUGA

↑↓

UNK

Yes↓

mmu-miR-5110

GGAGGAGGUAGAGGGUGGUGGAAUU

↑

UNK

UNK

mmu-miR-378a-5p

CUCCUGACUCCAGGUCCUGUGU

↑↓

UNK

Yes↑↓

mmu-miR-204-3p

GCUGGGAAGGCAAAGGGACGU

↑

UNK

Yes↑↓

mmu-miR-770-3p

CGUGGGCCUGACGUGGAGCUGG

↑

UNK

Yes ↓

mmu-miR-30a-3p

CUUUCAGUCGGAUGUUUGCAGC

↓

Yes

Yes↑↓

mmu-miR-1940

AUGGAGGACUGAGAAGGUGGAGCAGUU

↑

UNK

Yes↑

mmu-miR-674-5p

GCACUGAGAUGGGAGUGGUGUA

↑

UNK

Yes↑

mmu-miR-5128

CAAUUGGGGCUGGCGAGAUGGCU

↑

UNK

UNK

mmu-miR-182-5p

UUUGGCAAUGGUAGAACUCACACCG

↓

Yes

Yes↑

mmu-miR-151-5p

UCGAGGAGCUCACAGUCUAGU

↓

UNK

Yes↑↓

mmu-miR-125a-3p

ACAGGUGAGGUUCUUGGGAGCC

↑

UNK

Yes ↓

Table 5 : MicroRNA differently(p≤ 0.05) expressed in Treated (KGr, KGm and
KGG) compared to Untreated KPC mice[55, 56]. ↑= up regulated, ↓= down regulated,
UNK= unknown.
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3.2.2 Principle Component Analysis of microRNA Microarray
data:
In order to investigate the complete miRNA profiles and observe the differences
between treatment and non-treated groups we uploaded our whole miRNA data to
SIMCA P+ 13 software for multivariate analysis. Principle component Analysis is
unsupervised multivariate analysis which compresses large data sets into 2-3 principle
components. Based on the differences in these variables, each group was assigned a
point on the score plot. The separation between the groups represents differences in
microRNAs (variables). Score plot of the model with Untreated group (KC) compared to
Garcinol group (KGr) showed clear separation between the two groups. The
corresponding loading plot points toward the microRNAs responsible for this separation
Figure 26 and 27.

PC2
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PC1
Figure 26: PCA Score plot comparing microRNA profiles of KC and KGr group
(pvalue < 0.05).
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KC

Figure 27: Loading plot of model comparing KC with KGr group showed miRNA
responsible for separation of the two group.
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Loading plot of the model comparing KC group with KGr group (Figure 27) clearly
indicate that miRNA 21, miRNA 23 and miR 34 are responsible for KC score’s and
location and separation from KGr. These miRNA are reported to be tumor promoter
miRNA by several studies and microRNA data bases [55, 56].
In order to compare and to further investigate, we added a positive control group
(gemcitabine responders) KGm to this model. The score plot after addition of
gemcitabine responders, indicate that the separation of KGr is in the direction of
Gemcitabine treated mice. The score plot can also be predictive of response to
Gemcitabine and Garcinol. We can see that one Gemcitabine responder responded
more to the treatment compared to the other, as implicated by the distance of
separation from KC group Figure 28.

PC2
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PC1

Figure 28: PCA Score plot comparing microRNA profiles of KC, KGr and KGm
(responder) groups.
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KC

Figure 29: Loading plot of the model comparing KC with KGr and KGM (responder)
groups clearly showed miRNA responsible for separation of the KC group.
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Loading plot of the model with three groups (KC, KGr and KGm) Figure 29 again
pointed towards miRNA 21, miRNA 23 and miR34 responsible for separation of untreated KPC mice KC group from treated (KGm and KGr ) groups. In order to
specifically look at the effect Garcinol on the whole miRNA profile, we plotted
contribution plots of Garcinol points in the score plot (Figure 28).
The contribution plot gives us the information about the variable contributions
(microRNA) and their values for assigning certain location or locations in the score plot.
We can have contribution plot for one point and compare it to rest to see contributions
of that point , or we can have contribution plot of the whole group by selecting all the
score points from that group. We looked at the contributions of the whole KGr group.
The Contribution plot (Figure 30) indicated that positions of Garcinol scores on the
score plot were due to high values of many tumor suppressor miRNA and low values of
many tumor promotor miRNA labeled on the plot (Figure 30). Some of the tumor
suppressor miRNA found to have high values include miR 451a,miR 126-3p, mir5126,
miR149-3p, miR338,miR142 and miR29-3p. Tumor promotor miRNA with low values
includes miR23, miR243, miR27a, miR let 7, miR 21a-5p and miR341-5p and miR19b3p. Many of these miRNA were found statistically significant by ANOVA on Microarray
data validating this approach. Additionally it pointed out some miRNA responsible for
separation of complete miRNA profiles on score plot which were not statistically
significant but contributing in favorable manner as a group. This technique can be quite
useful with intervention studies where we have responders, non- responders to the drug
and also have variation in the data due to individual’s response to the drug.
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Figure 30: Contribution plot of KGr group explaining variables.
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3.2.3 mmu-miR 23a-3p:
MicroRNA 23a was found to be down regulated in Garcinol treated groups
compared to KC group (p value ≤ 0.05). This miRNA belongs to miR-130, miR-23 and
miR-23c family, it is located in the cytoplasm and is functional as mature miRNA. It is
considered to be an oncogenic miRNA, as it plays an important role in cell proliferation
and growth. MicroRNA mmu-miR-23a was found to be down regulated with Garcinol
treatment (KGr and KGG) compared to untreated KC group ( p value ≤ 0.02).
This miRNA was shown to be up regulated in several Gastrointestinal tract
Cancers including pancreatic cancer [53]. MicroRNA 23a is also reported to be up
regulated in lung cancer, endometrial cancer, uterine cancer, hepatocellular carcinoma,
melanoma and nasopharyngeal cancer. This microRNA is also deregulated in other
diseases including non -insulin dependent diabetes mellitus, cardiac fibrosis and
endometrial carcinoma (IPA, Ingenuity Systems Inc , Redwood City, CA).
Important targets for this microRNA includes IL6, FBX032 and TRIM63. In
addition it also binds to HES1, MDH2, ATAT1, LMNB1, SEPT3, SMAD5, SMAD3 &
SMAD4.
It can be regulated by multiple drugs like isoproterenol, decitabine, trichostatin A,
medroxyprogesterone acetate, beta-estradiol, androgen, 5-fluorouracil and proteins like
PASMC cells, AGO2, EPHB6, DIC ER1, SPI1, TNFSF12, E2F3, E2F2 (miRBase [57],
DIANA[58] & IPA, Ingenuity Systems Inc, Redwood City, CA).
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3.2.4 miR-23a~27a~24-2 cluster:
As many miRNA also exists in clusters and miR 23a is one of them. It is some
time observed to coexist as miR-23a~27a~24-2 cluster located at chromosome 8 .
These clusters are evolutionary conserved. Based on data from multiple research
studies it can take part in cell proliferation, differentiation and hematopoiesis together
[59]. This cluster can target Wnt signaling pathway, MAPK pathway, TGF-beta signaling
pathway, T cell receptor pathway, and Insulin signaling pathway, cytoskeletal
rho/GTPase pathway. This cluster can alter Wnt signaling pathway through different
target genes including APC,PP2A, CCND1[59].
In another study miR 23a regulated MTSS1 metastasis suppressor gene and
miR27a Targeted Ubiquitin ligase FBXW7 in colorectal carcinoma cell line , consistent
with the proposed role of miR23a as promotor of migration and invasion and miR 27 in
proliferation[60]. MicroRNA 23a is up regulated in intestinal adenocarcinoma at the
stage where they change from preinvasive to locally invasive stage where as miR27 is
normally up regulated in invasive and metastatic colorectal cancer[60].
In our study microRNA microarray data showed down regulation of miR23(p
value ≤0.02) , miR 27 (p value≤ 0.02) and miR24 (p value≤ 0.08). Further exploration of
this cluster’s target genes is warranted to understand the mechanisms and molecular
pathways involved in this pancreatic cancer mouse model. In a recent study from our
lab we have noticed down regulation of miR23a in Garcinol treated pancreatic cancer
cell lines. Data from this invivo study supported our invitro findings and points towards
possible relationship between Garcinol treatment and miRNA 23a.
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3.2.5 mmu-miR451a:
icroRNA 451a was up regulated (p value ≤ 0.05) in Garcinol treated mice (KGr
and KGG) this response was not observed in Gemcitabine responders ( KGm) in
microarray data.
miRNA- 451 is cytoplasmic miRNA and functionally active in its mature form. Its
gene is located on chromosome 17, 100bp downstream of miR-144 gene[61]. According
to the recent literature this microRNA behaves as tumor suppressor in several cancer
types. It is found to be one of the most stable miRNA and can be secreted into blood in
exosome affecting distant sites of its release location [62]. MicroRNA 451 is conserved
among vertebrates. Processing of miR 451 is little different than canonical miRNA
pathway as it bypass Drosha- mediated processing step [61].
It is reported to be involved in reducing tumor invasiveness, apoptosis and
arresting at Go/G1 phase. Links to several cancers have been reported especially
colorectal cancer, gastric cancer, lung cancer, renal cancer, acute lymphoblastic
leukemia and breast cancer. Some other disease where this microRNA was shown to
be involved are fatty liver, hyperglycemia with or without diabetes mellitus and
myelodysplastic syndrome.
Most common targets for miR 451 are CKND1B, CCND1, ABC B1, MMP9, BCL2
2 AKT1 and MMP 2. The expression of miRNA 451 gene can be regulated by
monocrotaline, acetoaminophen, proteins EPHB6 and AGO2.

It can also bind to

AKTIP, MIF and FBX033 genes (miRBase [57], DIANA[58] & IPA, Ingenuity Systems
Inc, Redwood City, CA). Notch 1 was also reported to be regulating levels of miR451 in
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T cell acute lymphoblastic leukemia, when intracellular notch 1 was induced it led to
down regulation of miR451 along with miR 709[63].
In a study conducted on colorectal cancer stem cell to identify markers for selfrenewal of cancer stem cells and drug resistance it was pointed out that miR 451 plays
a major role in both of these pathways[64]. After transfection with miR 451 reduced
number of colon spheres formation was observed, along with growth arrest and
sensitization to drug Irinecan metabolite in vivo. They also investigated Cycloxygenase2(COX2) and Wnt signaling pathway as possible mechanisms of these effects.
Additionally miRNA 451 can also act as biomarker for several cancers due to its
stability and presence in blood and other fluids. In recent studies healthy Gastric tissue
was shown to have higher concentration as compared to lower concentrations reported
in gastric cancer, likewise lower levels of miR451 about 170.9 fold reduction was
reported in non-small cell carcinoma[61]. In some of the recent studies specially in
formalin fixed paraffin-embedded (FFPE) cell blocks they have reported higher levels of
preserved mi451 levels as compared to other miRNAs in gastric cancer and Pancreatic
cancer FFPE blocks [61, 65].
Furthermore miR451 can also be used in cancer therapy to overcome drug
resistance and can be predictive of overall cancer survival as seen in Non-small cell
lung cancer patients. Patients with down regulation of miR451 were related to less
differentiation of tumors , late stage disease and lymph node metastasis [61].

3.2.6 RTPCR Validation of miRNA 23a and miR451:
In order to validate our microarray data we selected microRNA 23a and
microRNA 451 for real time reverse transcriptase polymerase chain reaction (RTPCR)
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gene expression analysis. As miR23a was found to be down regulated and miR 451
was up regulated looking at the expression profiles of these miRNA clearly supported
microarray findings. MicroRNA 23a was found to down regulated in KGr and KGm
responders groups (Figure 31). Expression of miRNA 451a was up regulated only in
Garcinol treated groups (KGr and KGG) Figure 32 compared to KC and KGm group.
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Figure 31: MicroRNA 23a levels by microarray and RTPCR. A, miRNA 23a
microarray levels were found to be lower in KGr, KGm responder and KGG (‘a‘ is
significantly different to ‘b’ pvalue ≤ 0.05) Error bars represents ± mean standard
deviation. B, miRNA 23a expressions RTPCR were down regulated in KGr and KGm
responder (less than 0.5 fold compared to KC). KGr and KGm were significant based on
t-test (‘a’ is significantly different from ‘b’ p value ≤ 0.05)
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Figure 32: MicroRNA 451a levels by microarray and RTPCR. A, miRNA 451 levels
were found to be higher in KGr and KGG (‘a‘ is significantly different to ‘b’ pvalue ≤
0.05). Error bars represent ± mean standard deviation. B, miRNA 451a expressions
were up regulated in KGr and KGG (almost 2 fold compared to KC). KGr and KGG were
significant based on t-test (‘a‘ is significantly different from ‘b’ p value ≤ 0.05)
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Pancreatic mRNA expression levels of some of target genes by
RT PCR:
Four target genes from miRNA found to be differently expressed with Garcinol
treatment were selected for investigation in pancreatic tissue. These four genes were
Matrix metalloproteinase 9 (MMP9), Cyclin D1, B-cell lymphoma 2 (Bcl2) and Notch 1.
These genes belongs to four different pathways of tumorogenesis and are considered
as tumor promotor genes.

3.2.7 Matrix metalloproteinase-9 (MMP9):
Pancreatic mRNA expressions of MMP-9 gene were found to be significantly
decreased in Garcinol (KGr) and Gemcitabine plus Garcinol (KGG) group compared to
non-treated KC group(fold change). Interestingly Garcinol groups (KGr and KGG
significant based on ttest pvalue <0.05) showed lower MMP 9 levels compared to KGm
group due to KGm responders and non-responders the average for KGm was even
higher than KC. The combination group KGG showed the lowest levels of MMP9 among
all groups (Figure 33).
MMP9 belongs to matrix metalloproteinases (MMPs) family they are Zinc –
dependent endopeptidases can also be called as matrixins. Involvement of
metaloproteinases in tumor metastasis is been investigated in many studies. They have
shown to increase angiogenesis, enhance invasion and aid secondary tumors growth
at metastatic sites[66]. In this Family of proteins, MMP9 has been repeatedly reported
to be involved in angiogenesis and invasion. High levels of serum MMP 9 was reported
to be linked with proliferation, metastasis and poor survival in melanoma patients. In
another study MMP9 serum and plasma levels were related to metastasis of rat
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mammary tumors[66]. Additionally it can be a marker of invasiveness, as higher MMP 9
expressions were shown to be related to chemically induced skin tumors specially
invasive carcinoma[66]. High expression of MMP 9 was also associated with lymph
node metastasis of ovarian carcinoma cells[67]. Additionally higher MMP 9 expression
was related to poor prognosis in breast cancer patients[67]. Lower expressions of
MMP9 in Garcinol groups can be indicative of lower invasiveness of pancreatic cancer
in these mice.
Lower expressions of MMP 9 levels in this study correlates with the invitro data
from our lab in Pancreatic cancer cell line with Garcinol treatment. Gemcitabine only
had 10-15% response based on our MRI data but the combination of Gemcitabine and
Garcinol had lower MMP9 expressions as a group (more consistent).
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Figure 33: RTPCR mRNA expression of MMP 9 in KC, KGr, KGm and KGG groups.
KGr and KGG had lower expression relative to KC ( less than 0.5 fold). Fold change
was calculated by 2-∆∆CT method. β-actin was used as house-keeping gene to
normalize CT values. KGr and KGG statistically significant (t-test- ‘a‘ is significantly
different from ‘b’ p value < 0.05). MMP9 expressions were very different in KGm
responder and Non responder (not significant)..
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3.2.8 Cyclin D1 (CCND1):
Relative mRNA expression of CCND1 gene in pancreatic tissue samples indicate
lower expression levels for KGr, KGm and KGG groups compared to non- treated KC
group. Additionally dietary Garcinol (KGr and KGG groups) was found to be more
effective in reducing CCND1 levels in comparison to Gemcitabine treatment (KGm
group) Figure 34.
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Figure 34: RTPCR mRNA expression of CCND1 in KC, KGr, KGm and KGG
groups. KGr and KGG had lower expression relative to KC (less than 0.5 fold). Fold
change was calculated by 2-∆∆CT method. β-actin was used as house-keeping gene to
normalize CT values, KGr and KGG significantly different from KC (t-test - ‘a‘ is
significantly different from ‘b’ p value < 0.05). KGm responder and non-responder had
very different mRNA expressions (not significant).

91
Cyclin D1 is a cell cycle gene involve in progression through the G1-S phase, it
phosphorylates retinoblastoma gene (Rb) promoting cell proliferation. Up regulation of
CCND1 gene is observed in many cancers[68]. It belongs to cyclin Family members of
which is phosphorylated by cyclin dependent kinases CDK. Beside its function in cell
cycle, it also act as regulator of transcription factors and other coactivators

and

corepressors. These factors can lead to histone acetylation and chromatin
remodeling[68]. It is also reported to be involved in cell differentiation, migration and
metabolism[68]. Overexpression of CCND1 is shown to be related to gene amplification
and deregulation at post translational level [69]. Our non- treated group showed higher
levels of CCND1 and these levels are were significantly reduced after Garcinol
treatment. CCND1 can be regulated by miRNA 451a and miRNA 23a. As reported by
earlier studies, overexpression of CCND1 is not solely due to genetic reasons,
epigenetic regulation also plays important role, further investigation with miRNA mimics
and inhibitors can provide valuable information. We saw the similar response as MMP9
in CCND1 with Gemcitabine and Garcinol treatment, as the Garcinol treated groups
were more consistent in lowering CCND1 levels.

3.2.9 B-cell lymphoma-2 (Bcl2):
RTPCR mRNA expression profile shows no significant fold change in treated
groups (KGr, KGm and KGG) compared to non-treated group (KC) Figure 35. Bcl2
belongs to Bcl family of proteins these proteins can be pro apoptotic or antiapoptotic
[70] . Bcl2 is particularly is an antiapoptotic protein involved in Bax dependent
mitochondrial apoptotic pathway. Bcl 2 is documented to be overexpressed various
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cancers[71].. Bcl2 blocks the release of cytochrome C from mitochondria resulting in
disruption of caspase dependent apoptosis [72].
Bcl2 can be regulated by miR 451a (Gene View, IPA , Ingenuity Systems Inc,
Redwood City, CA) but results from pancreatic tissue were expected as our model was
p53 conditional mutant in pancreas. Protein p53 acts as check and regulator of Bcl2
through Puma and noxa [73]. Furthermore p53 induce Bax, an pro apoptotic protein
which minimize the effects of Bcl2 on apoptosis[73]. This is the reason why Bcl2 vs.
bax ratio actually gives the complete picture of effects Bcl2 on apoptosis. In addition to
this, in case of crises like situations, in most tumor environment p53 can directly repress
Bcl2 as Bcl2 promotor has p53 negative response element[73]. We can assume that
high levels of Bcl2 could be due to lack of p53 in the pancreatic tissue.
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Figure 35: RTPCR mRNA expression of Bcl 2 in KC, KGr, KGm and KGG groups.
There was no significant change observed among all the groups. Fold change was
calculated by 2-∆∆CT method. β-actin was used as house-keeping gene to normalize
CT values (t-test - p value > 0.05).
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3.2.10 Notch1:
Relative expression of mRNA RTPCR analysis with Notch1 genes showed
significant down regulation of Notch1 in both Garcinol treated groups (KGr and KGG) in
comparison to non-treated KC group. Garcinol treatment showed reduction of Notch1
mRNA profile when compared to KGm (Gemcitabine).also. Surprisingly Garcinol alone
had lowest values among all the groups (Figure 36). KGr and KGG showed more
consistent values compared to KGm which had clear responders and non- responders
and the average of the group showed higher expression compared to KC, when we
separated responders and non-responders, we were able to the response of
Gemcitabine in KGm group on Notch1 mRNA levels.
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Figure 36: RTPCR mRNA expression of Notch 1 in KC, KGr, KGm and KGG
groups. KGr and KGG had lower expression compared to KC (less than 0.5 fold). Fold
change was calculated by 2-∆∆CT method. β-actin was used as house-keeping gene to
normalize CT values. KGr and KGG were significantly different from KC (t-test - ‘a‘ is
significantly different from ‘b’ p value < 0.05).
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Activation of Notch1 is reported in multiple cancers. Although the mechanistic
targets and molecular mechanisms are still under investigation, it plays a critical role in
tumor proliferation [63] . Notch signaling is dependent upon its interaction with family of
ligands leading to activation of these proteins[74]. Upon activation, the cleaved Notch
enters the nucleus. This cleaved Notch along with transcription factors can regulate
gene expression of target genes. Notch is also reported to be involved in cellular
differentiation and its dysfunction can leads to tumor progression. Notch1 can also
regulate and inhibit apoptosis through its interaction with NFkB and other related factors
[75].

In a recent study a link between miRNA 451 suppression after induction of

intracellular Notch1 had been investigated. They have reported that Notch 1
overexpression can degrade tumor suppressor E2a which is responsible for
transcriptional activation of microRNA 451 and microRNA 709. Activation of miR451
and miR 709 are responsible for suppression of Myc, Akt and Ras-GRF1 (reported
oncogenes)[63]. Our investigation of Notch1 leads to a possibility that Notch1
overexpression in KC mice might have a correlation with lower miRNA 451 levels.
Treatment with Garcinol have shown to decrease Notch1 levels along with up regulation
of miR451.

3.2.11 Liver mRNA expression levels of some of target genes by
RT PCR:
In order to investigate the mRNA expression profiles of target genes at one of the
common metastatic site we selected liver. Liver is one of the first organ where
Pancreatic ductal adenocarcinoma metastasize.
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3.2.12 Liver CCND1 mRNA expression:
Liver CCND1 mRNA expression showed significant reduction in All treated
groups (KGr, KGm and KGG) compared to non-treated KC group. KGG group shows
lowest expression among all three treated groups Figure 37. Lower levels of cyclin D1
can be representative of lower metastasis proliferation in treated groups. Liver CCND1
profile correlate with pancreatic CCND1 mRNA profiles from Garcinol treated mice
supporting the anti-cancer effect of Garcinol.
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Figure 37: Liver RTPCR mRNA expression of CCND1 gene in KC, KGr, KGm and
KGG groups. KGr, KGm and KGG had lower expression relative to KC (less than 0.5
fold). Fold change was calculated by 2-∆∆CT method. β-actin was used as housekeeping gene to normalize CT values. KGr and KGG were significantly different from
KC (t-test - ‘a‘ is significantly different from ‘b’ p value < 0.05)
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3.2.13 Liver MMP9 mRNA expression :
Liver MMP9 mRNA profiles from Garcinol treated groups (KGr and KGG) showed
significant reduction relative to non- treated KC group. KGm group showed trend of
reduction in mRNA expression but was not significant (more than 0.5 fold) Figure 38.
Liver MMP9 mRNA expression profiles correlate with pancreatic mRNA levels and both
showed significant reduction with dietary Garcinol treatment.
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Figure 38: Liver RTPCR mRNA expression of MMP9 in KC, KGr, KGm and KGG
groups. KGr and KGG had lower expression compared to KC (less than 0.5 fold).KGm
showed lower expression trend but not significant. Fold change was calculated by 2∆∆CT method. β-actin was used as house-keeping gene to normalize CT values. KGr
was significantly different from KC (t-test - ‘a‘ is significantly different from ‘b’ p value <
0.05)
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3.2.14 Liver Bcl2 mRNA expression :
Relative expressions of Bcl2 gene compared to KC group in liver tissue showed
significant reduction in both Gemcitabine (KGm) and Combination group (KGG). A trend
was observed in KGr group but was no significant reduction compared to KC group
Figure 39. Gemcitabine treatment was able to reduce Bcl2 levels significantly in liver
tissue compared to no effect in P53 mutant pancreatic tissue.
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Figure 39: Liver RTPCR mRNA expression of Bcl2 in KC, KGr, KGm and KGG
groups. KGm and KGG had lower expression compared to KC (less than 0.5 fold). KGr
showed trend (more than 0.5 ). Fold change was calculated by 2-∆∆CT method. β-actin
was used as house-keeping gene to normalize CT value. KGr, KGm and KGG were
significantly different from KC (t-test -‘a‘ is significantly different from ‘b’ p value < 0.05)
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CHAPTER 4: Urinary Metabolomics profiles of
Garcinol treated Pancreatic Cancer transgenic mice
Metabolomics is a relatively new approach to identify differences in the larger
complex data sets usually collected from biological samples. It is one of the omics
approach dealing with the overall changes in the metabolism associated with either
disease processes or treatment interventions. With growing advances in the omics
fields, it can change current concepts of diagnosis and treatment, making it more
tailored for custom need of the individuals. These advancements have rendered
traditional approaches to be limited and less appropriate for today’s clinical
environment, where we have genome and metabolome wide information available.
Complex metabolic diseases are usually associated with interconnections of variable
factors leading to overall presentation of the disease state [76].
There is an added interest in the biomarker discovery for early diagnosis and
treatment, making metabolomics one of the technique most pursued in this field. It is the
study of low molecular weight, less than 1500 Daltons compounds. These compounds
collectively make the metabolome, which can potentially provide exclusive information
about the disease or tested treatment outcome[77]. Recently the introduction of latest
data analysis tools including multivariate data analysis and pattern recognition software
have aided analyzing complex data such as those produced from metabolomics, with
much ease [76].
Investigation of urinary metabolomics profiles is a non -invasive and cost
effective technique, which can provide unique signatures and information about the
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alterations in metabolism with disease, treatment and environmental changes. In this
study, we first studied the biomarkers of Pancreatic cancer in urinary metabolomics
profiles of KPC mice by comparing them with those of the control littermates without
mutations leading to cancer. Secondly, we investigated the changes associated with the
progression of pancreatic cancer. Additionally the main goal of the study was to
investigate the effects of Dietary Garcinol treatment on urinary metabolomics profiles of
KPC mice.

4.1 Methods:
4.1.1 Urine Sample preparations:
Urine samples were collected in weeks 2, 4 and 6. Mice were kept in suspender
for 24 hours. The Urine samples were collected. Samples were centrifuged at 1500 rpm
for 2 minutes to remove solid debris and 0.02% wt/vol sodium azide (NaN3) was added
to urine samples as an antibacterial agent. Urine samples were stored in -80° C till NMR
analysis. For NMR spectroscopy samples were thawed at room temperature and diluted
in a ratio of 1:4 with Deuterium oxide (D2O).
A reference buffer solution of 5mM DSS (disodium-2, 2-dimethyl 2-silapentane-5sulphonate) and 10mM imidazole (pH indicator) in D2O (Deuterium Oxide) (SigmaAldrich, Mississauga, ON) were added in a ratio of 9:1 (9 urine: 1 NMR solvent) to the
diluted samples. Samples were mixed by vortexing and were transferred to 8 inch NMR
tubes (Kontes glass, Vineland, NJ) [78].
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Samples were prepared based on recommendations from CHENOMX software
database which was used for interpretation of peaks in NMR spectra. Samples were
prepared in the morning of NMR as they can detoriate over time.

4.1.2 1H-NMR Spectroscopy:
1

H-NMR spectroscopy was conducted on Varian 500 MHz with oxford

magnet (Varian, Palo Alto, CA). It is equipped with 5mm AutoX , broadband
(15N-31P/1H-19F) probe with variable temperature capabilities. VNMRJ software
was used to collect spectral data in the form of free induction decay (FID) files in
time domain. NMR spectroscopy was conducted according to the setting and
pulse sequence required by CHENOMX software-1D version of noesyprtp; with
pre-saturation during relaxation delay and mixing time. Briefly temperature of the
probe was set at 25° C with pulse sequence tnnoesy. Total of 64 scans were
collected using acquisition time of 4 seconds with sweep width of 6009.62 hzs
and 32768 number of points at 500 MHz frequency.

4.1.3 Pre- processing of NMR spectra using ACD 1D NMR
software:
NMR spectra were collected in Free Induction Decay (Fid) time domain format
we converted them in frequency domain in order to analyze them by the multivariate
analysis software. Fid files were Fourier transformed to frequency domain Figure 40.
Fourier transformed spectra are represented by spectral width of 10 ppm, with spectral
regions (peaks) representative of different metabolites in the sample. We used 1D
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NMR preprocessing software, ACD/Spec Manager 7.00 software (Advanced Chemistry
Development, Inc. Toronto, Ontario, Canada) for this processing. The spectra obtained
were pre-processed in one file, baseline corrected and auto phasing was done using
DSS peak as a reference at 0.0 ppm. The spectra after preprocessing had straighter
base line and sharper peaks Figure 41. The spectra were divided into 1000 bins by
intelligent binning, to avoid splitting of the peaks into two bins. These binned spectra
were digitized into table of integrals and were exported to Simca P+ (13) software.
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Figure 40: Fid files from NMR 500 stacked in one file in ACD/Spec Manager 7.00
software
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Figure 41: Fourier transformed spectra stacked using ACD/Spec Manager 7.00
software.
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4.1.4 Multivariate data Analysis:
The table of integrals from ACD software were imported in the SIMCA P+
software (Umetrics Academy, Sweden) for Multivariate data analysis (MVDA). The
imported data was converted to a model, using Principle component analysis (PCA).
PCA is an unsupervised mathematical algorithm which can be used as a screening tool
to study the differences between the urinary spectra from different groups. A Principle
component (PC) is a weighted linear combination of all the NMR variables. The huge
data set of original variables is compressed into few PCs [79]. Normally NMR data is
compressed into 3-4 PCs, while most of the variation is explained in first principle
component. The area of spectrum before 0.5 ppm and area from 4.5 to 5.5 was
removed from the spectrum before analyzing the data with PCA. This region contains
peaks from water, urea and other exchangeable protons. The NMR spectra also
contains small peaks due the metabolites present in small concentrations. In order to
give them equal importance as the larger peaks (metabolites present in higher
concentrations), we used Pareto scaling. Pareto scaling is mean centering followed by
dividing with square root of standard deviation of the original variables. Scatter plots and
loading plots were analyzed and groupings were observed based on the differences in
the urinary HNMR spectra.
Large complex data set like NMR spectra have large number of X variables. This
kind of data set cannot be analyzed by traditionally used statistical analysis tools. The
margin of error increases with rise in number of X. variables with techniques like
ANOVA etc. PCA, a mathematical algorithm which compress the original data matrix
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and can successfully project observations on scatter plot based on the loadings of that
observation.
Loading plots pointed toward the ppm responsible for these separations. The
ppm identified by loading plot responsible for separation of the different groups, were
further investigated to identify the metabolites responsible.

4.1.5 Analysis to identify and quantify the differences in
metabolites concentrations:
The areas on the spectrum responsible for separations in the PCA were explored
and the metabolites in the area were identified and quantified using CHENOMX NMR
suite (CHENOMX INC, Edmonton, Alberta). The fid files from the 1D 1H –NMR spectra
were imported to the CHENOMX software. This software had its own processing
interface where spectra were Fourier transformed and base line was corrected. Phasing
was done using DSS reference peak at 0.0 ppm and water peak was deleted. The
processed spectra were analyzed in the profiler module of the software. The 500 MHz
library with corresponding pH was selected; this library contained more than 300
metabolites. Identification and concentrations of different metabolites was calculated by
fitting the set of peaks for those compounds in the sample spectrum. If the area was
crowded with many peaks then multiple metabolites were fitted at one time to match the
reference spectrum closest to the sample spectrum [79]. The identified and quantified
compounds were then exported to the Excel sheet and ANOVA and t test were done to
calculate the statistical significance of the differences in spectra.
DSS is used as chemical shape indicator and reference standard to calculate the
concentrations of different metabolites. It is very important to have sharp and clear DSS
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peak in the spectra to identify and quantify the metabolites using CHENOMX software.
Imidazole added to the samples was used to as pH indicator. As the peaks shifts with
differences in pH, the metabolite library was selected based on pH. Pathways involved
were explored using KEGG database. Summary of methods used for metabolomics
analysis of urinary HNMR spectra are listed in Figure 42.

KPC Mice

Urine Sample collection

HNMR 500 MHz

ACD , Fid files
processing and Binning

CHENOMX Targeted
profiling

PCA multivariate analysis

Figure 42: Flow chart of steps required to investigate the differences in Urinary
Metabolomic profiles.
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4.2 Results and Discussion:
NMR is a suitable technique for bio fluids as the samples preparation is
comparatively simple and samples can be reused after the spectroscopy. We have very
detailed database for metabolite available in CHENOMX. NMR technique provide
quantative information and is reproducible, hence suitable for multivariate analysis[80].
NMR is not dependent on the hydrophobicity of the metabolite and is more suitable for
metabolomics analysis of complex biological systems[80]. DSS was used as a
reference for NMR spectra due to its less electronegative structure. It has shielded 9
methyl groups due low electronegativity of silicon. It gives signal upfeild and usually set
as 0.0 ppm as this signal is further upfeild as compared to all organic compound .TMS
is used as solvent for organics, as DSS is more water soluble it is used in most
biological water based samples like urine saliva etc. As the CHENOMX software has
the library for metabolites which are dependent on pH of the sample, Imidazole was
added as pH indicator. The peaks of imidazole are pH dependent and its chemically
inert nature makes it a perfect pH indicator in the biological samples[81].

4.2.1 Principle component Analysis (PCA):
4.2.2 To investigate the differences in metabolomic profiles of
mice with and without pancreatic cancer.
In order to find the differences between urinary metabolomics profiles (MP) of
control no cancer CC group and non-treated cancer group (KC). We made a model with
1

H-NMR spectra from CC and KC at week 6 of the study. As shown in Figure 43, the

two groups were separated in the score plot along PC1 which contains the maximum
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explained variation in the data, indicating that there were differences in metabolomics
profiles of cancer group compared to non- cancer group. The corresponding Loading
plot for this PCA model pointed towards the metabolites (ppm) responsible for this
separation (Figure 44). These peaks responsible for separation of the two groups could
be potential biomarkers of Pancreatic Cancer in this p53 and Kras conditional mutant
pancreatic cancer mouse model.

PC2
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Figure 43: PCA Score plot showing differences metabolomics profiles of Cancer
(KC) and no cancer (CC) groups.
(p value < 0.05)
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Figure 44: Potential biomarkers of cancer in KPC mice model.
PCA loading plot showing regions of NMR spectra responsible for the differences in MP
of CC and KC groups shown in corresponding score plot (Figure 43).
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4.2.3 To investigate changes in urinary metabolomics profiles
upon progression of pancreatic cancer.
In order to investigate the changes in metabolism and metabolite excretion with
progression of Pancreatic Cancer (PaCa) from week 2 to week 6 in non- treated KC
group, we made a model with 1H-NMR spectral files from KC group at weeks 2 and 6.
The score plot showed separation of the two groups along PC 1 and PC2. Separation of
the two groups on the score plot represents differences in urinary metabolomics profiles
(MP) of KC group at week 2 and 6 (Figure 45). The corresponding loading plot of the
model showed the regions of spectra (ppm) responsible for the separation in the score
plot. These metabolites represented in the spectral regions could be possible
biomarkers for PaCa progression in KC mice. Interestingly some of the spectral regions
responsible for differences in the MP between week 2 and 6 of KC mice were similar to
the areas responsible for differences in Control no cancer CC and non-treated KC mice
at week 6. These results indicate that some of the metabolites (ppm) which were altered
due to Pancreatic cancer incidence can also be changed, possibly in concentration with
PaCa progression. These metabolites need to be studied further for their potential use
as biomarkers for progression and diagnosis.

PC2
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PC1

Figure 45: PCA Score plot showing Changes in Metabolomic profiles with
progression of pancreatic cancer in animals of KC group from week 2 to 6.
(p value < 0.05)
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KCW2

KCW6

Figure 46: Potential biomarkers for Pancreatic cancer progression.
Loading plot showing regions of NMR spectra (ppm) responsible for separation in score
plot of Metabolomic profiles of KC mice at week 2 and week 6.
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4.2.4 To investigate the diffrences in MP due to dietary
intervention with Garcinol:
In order to study the effects of Dietary Gacinol on urinary Metabolomic profiles
we compared 1H-NMR spectra from KC and KGr (Garcinol treated) mice at week6 of the
study. Score plot of this model showed seperation between the two groups compared
indicating differences in 1H-NMR spectra from KC and KGr groups (Figure 47). Loading

PC2

plot explains the variables (ppm) responsible for seperation Figure 48.

PC1

Figure 47: PCA score plot showing changes in Urinary metabolomic profiles of
KPC mice with dietary Garcinol.
KC and KGr groups at week 6 were seperated on principle component1 and 2(p value <
0.05).
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KC

KGr

Figure 48: PCA Loading plot KCand KGr at week 6.
PCA Loading plot showing spectral regions responsible for seperation of KC and KGr
groups at week 6.
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4.2.5 Investigation of MP from KC, KGr and KGm groups at
week 6 :
As we have noticed differences in Urinary metabolomics profiles of KC and KGr
at week 6, we wanted to investigate whether these differences have any similarities with
Gemcitabine treated mice (KGm), our chemotherapy group in the study. The score plot
of the model with KC, KGr and KGm week 6 showed that KGr group’s separation was in
the same direction of KGm group. Differences between Gemcitabine responders and
non-responders can also be predicted from this plot based on the distance between the
individual KGm score and KC Group. Some of the KGr scores were further away,
different from the separation of KGm responders Figure 49. The loading plot of this
model pointed toward the variables (metabolites) present in different concentration in
KGm, KGr and KC group. Some of the variables (ppm) were common to the CC and KC
week2 in treatment group indicating their consistent role in Pancreatic cancer
progression and treatment (ppm 5.79. 5.8 related to KC and 3.26-3.43, 4.3 related to
CC, KGr and KGm etc.) Figure 50.
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PC2

A

PC1

B

Figure 49: PCA score plot of groups KGr, KGm and KC week 6.
A, Showing KGr are separated from KC in the same direction of KGm (p value < 0.05) .
KGr scores were closer to KGm on Principal component 3 as shown in 3D score plot.
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KGm& KGr
KC

Figure 50: Loading plot explaining metabolites present in different concentrations
in urine of KPC mice after treatment with Gemcitabine and Garcinol.
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4.2.6 Investigation of MP from KC, KGr, CC week 6 and KC
Week 2 groups:
In order to investigate the seperation of KGr score points which were further
away not in the direction of KGm reponders we made a model adding CC and KC week
2 along with KC and KGr week 6. Surprinsingly the score plot explains the seperation of
KGr from KC week 6 in a new way. Some of the KGr week 6 scores were among CC
( no cancer control) and some of the KGr scores were among KC week 2 scores Figure
51. This Urinary H-NMR data indicate that treatment with Garcinol has either treated
KPC mice or have retarded the progression of

Pancreatic cancer. Both ways the

burden of the disease has been lessened, reflected by the differences in metabolomic
profiles of KGr week6 from KC week 6.

Corresponding Loading plot of this model

explains the variables responsible for seperation after treatment Figure 52. The ppm
associated with KC week 6 seperation with progresssion of disease compared to KC
week 2 include 3.26-3.45 region along with 7.79- 7.8 region these ppm were also found
to be different from KGr and CC groups in previous models.

PC2
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PC1
Figure 51: PCA score plot showing changes in Urinary metabolomic profiles of
KC, KGr, CC week 6 and KC week2.
KGr score are positioned near CC and KC week 2 indicating retardation of pancreatic
cancer growth with dietary Garcinol intervention (p value < 0.05).
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CC

KCW2
KC

Figure 52: Loading plot of PCA KGr week 6, CC week 6, KC week 2 and 6.
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4.2.7 CHENOMX, Metabolites identification and quantification:
Each spectrum was imported to CHENOMX NMR suite as fid file and processed
in the processor module of the software. Processed spectrum was imported to profiler
module of the software. Each peak was matched with metabolites present in that area
and spectrum was fitted to identify and quantify the metabolites present in the urinary HNMR spectra from KPC mice groups. Five spectra from each group were fitted in the
profiler interface with metabolite directory containing more than 300 compounds. The
profiled compounds were exported to Excel files and compounds found to be different
among groups were analyzed by ANOVA (SPSS software) and t-test for statistical
significance. Metabolites found to be different among KC, KGr, KGG and KGM groups
week6 along with ppm for peaks identified, are listed in Table 6. Metabolites found to
be significantly different in groups are listed in Table 7.
Additionally it was observed that concentration of urea was higher in KC
(untreated KPC) group compared to CC, KGr and KGm groups (p value> 0.05, not
significant). The ppm 5.79- 5.8 representing Urea peak were strongly related to KC
group in all the PCA loading plots.
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Table 6: Metabolites found to be in different concentrations in Urinary spectra of
KPC mice .
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Table 7: Compounds found to be significantly different in KC, KGr, KGG and KGm
groups. Tartrate and phenylacetate were only significantly different in KGr from KC
group(p< 0.05) not in KGm group.
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4.2.8 Allantoin:
Allantoin is oxidative product of Urate which is an end product of purine
metabolism. As urate has anti-oxidative properties, it oxidation can lead to allantoin
production and which can be a marker of oxidative stress [82]. Several studies have
shown correlation of allantoin excretion in urine with oxidative stress. Recently urinary
allantoin is considered as a known marker of oxidative stress and several studies have
reported it along with isoprostanes and other oxidative markers [83, 84]. In one of the
study they compared to TBARs and have concluded that Allantoin is better and stable
marker of oxidative stress than TBARS. Allantoin levels were stable indicating it
represents the internal oxidative stress not by urate just produced during temporary
exercise [85].
In Urinary H-NMR spectra peaks from allantoin comes around 8.0, 7.3, 6.0 and
5.4 ppm. One of the peak in NMR spectrum is shown in Figure 53. Although the peak
comes near urea, it can be fitted and quantified. The levels of allantoin were significantly
decreased in urinary NMR spectra from Garcinol treated KGr group and KGm group as
compared to KC group (Figure 54).
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Figure 53: Allantoin peak around 6 ppm.
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Figure 54: Urinary Allantoin concentrations in KC, KGr, KGG and KGm week 6.
KGr and KGm are statistically significantly different compared to KC (‘a‘ is significantly
different to ‘b’ p value <0.05). Error bars represents standard deviation.
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4.2.9 Phenylacetate:
Phenylacetate is a terminal product of Phenylalanine and Phenylethylamine
metabolism [86]. Can be a mood indicator , and has antidepressant effect of exercise
due to amphetamine like action of Phenylethylamine [87]. Its levels are very high in
patients with phenylketone urea patients. Our mice were severely ill mice and we
observed mostly lower phenylacetate levels in KC (week 6) mice compared to KCW2
and CC mice Figure 55. Phenylacetate levels were increased with treatment with
Garcinol in KGr group Figure 56. Although Gemcitabine (KGm) and combination group
(KGG) showed increasing trend but were not significant due to high standard
deviation(responder and non-responders).
Phenylacetate has been reported to have anti-cancer effects also. In a study
conducted on renal cancer cell lines phenylacetate treatment have inhibited growth.
Main target of phenylacetate was p21CIP1 but it also caused inactivation of CDK2,
hypophosphorylation of pRb. leading to G1 cell cycle arrest[88]. It has also shown to
improve sensitivity of multidrug resistant breast, ovarian and colon tumor cell lines
when treated along with phenylbutyrate [89]. Phenylacetate is also reported in clinical
trial conducted on 17 advanced solid tumor patients where it has been reported to
stabilize 3 prostate cancer patients and decreased bone pain in one patient. One of six
glioblastoma patient showed improvement over nine month [90].
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Figure 55: Urinary Phenylacetate levels decrease with progression of pancreatic
cancer and in KC compared to CC mice.
Although not significant (p value KCW2=0.068 and CC= 0.082) but showed trend. Error
bars represent standard deviation.
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Figure 56: Phenylacetate levels in KCW6, KGrW6, KGGW6 and KGmW6.
KGr is significantly different from KCW6 (‘a‘ is significantly different from ‘b’ p value <
0.05).Error bars represents one standard deviation.
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4.2.10 Tartrate:
Tartrate excreted in urine is mainly from diet and about 15 to 20 percent of
tartrate ingested is excreted without change. Tartrate is mostly metabolized by intestinal
bacteria and tissue metabolism is very slow [91]. Urinary tartrate excretion is high in
males and vegetarian people have lower tartrate in urine. It poses antioxidant activity
and is powerful chelating agent. Urinary tartrate is a reported to be protective against
kidney stone formation, as it can form stable soluble complexes with calcium. Tartrate is
also investigated for it effects as an inhibitor of surface controlled crystallization similar
to the effects of citrate on this process[91].
In H-NMR spectra Tartrate peak comes around 4.3ppm as shown in Figure 57.
Figure 58 illustrate Tartrate metabolic role in Glyoxylate and Dicarboxylate
pathway.
Urinary tartrate excretion was lower in KC mice at week 6 compared to CC (p
value < 0.05) and showed a decreasing trend from KC week 2 to week 6 Figure 59.
Indicating that Pancreatic cancer and its progression can have lowering effect on
urinary Tartrate levels. Tartrate was found to be increased in concentration in Garcinol
treated KGr group compared to KC mice Figure 60.
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Figure 57: Tartrate peak at 4.3 ppm.
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Figure 58: Role of Tartrate in Glyoxylate and Dicarboxylate metabolism.
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Figure 59: Urinary Tartrate levels decrease with progression of pancreatic cancer.
Tartrate is significantly higher in CC compared to KCW6. (‘a‘ is significantly different
from ‘b’ p value < 0.05). Error bars represents one standard deviation.
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Figure 60: Urinary Tartrate concentrations in KC, KGr, KGG and KGm week 6.
KGr is statistically significantly different to KC (‘a‘ is significantly different from ‘b’ p
value <0.05). Error bars represents ± standard deviation.
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4.2.11 Taurine:
Taurine is an amino and sulphur group containing organic acid commonly
present in most tissues of the body, including heart brain and liver. A very little is known
about its involvement in major metabolic pathways, It is involved in methionine and
cysteine metabolism.[92]. Its role in bile has been elucidated by several studies, bile
acids are conjugated with taurine and these conjugates works as detergents in bile [93].
Multiple other roles of taurine have been reported. It helps maintaining osmotic balance
and membrane potential of cells and mitochondria. Helps lowering superoxide synthesis
in mitochondria [94]. It has shown to improve cardiovascular health and antihypertensive, anti-diabetic effects [94]. It is also known to have Hypoglycemic action,
anti-oxidation, and detoxification [92]. Taurine is also found to be effective in pancreatic
islets remodeling against cytokine-induced apoptosis [92].
Serum taurine levels are reported to be lower in many cancer types including
breast, ovarian, endometrial and colon cancer. In a clinical study, serum taurine levels
were found to be very low in female breast cancer patients (p value 0.001), possible
reason to taurine depletion, as discussed by researchers, is that the
produce a very large number of

tumor cells

sulphate polysaccharides utilizing and depleting

sulphur containing taurine in the surrounding. As the detection was 100 percent with no
false positives, they proposed taurine as a biomarker for breast cancer diagnosis [95].
Taurine peaks are very distinct peaks around 3.2-3.45 ppm in Urinary H-NMR
spectrum. Figure 61 shows taurine peaks fitted on CHENOMX software. Metabolic
pathway of Taurine and hypotaurine metabolism is illustrated in Figure 62.
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KPC mice showed a trend in reduction of taurine urinary levels with progression
of cancer (P value >0.05) Figure 63. KC mice had very low concentration of taurine at
week 6 which is improved after Garcinol and Gemcitabine treatments as observed in
Figure 64. Urinary Taurine levels were higher in KGr and KGM group after 6 weeks
treatment.

Figure 61: Fitted Taurine peaks near 3.2- 3.45 ppm.
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Figure 62: Taurine and Hypotaurine metabolism (KEGG Ligand database).
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Figure 63: Urinary Taurine levels showed a decreasing trend with progression of
pancreatic cancer in KC compared to CC mice (p value > 0.05).
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Figure 64:Urinary Taurine concentrations in KC, KGr, KGG and KGm week 6.
KGr and KGm are statistically significantly different to KC (‘a’ is significantly different
from ‘b’ p value <0.05). Error bars represents standard deviation.
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CHAPTER 5: Conclusions
We investigated the response of KPC mice with k-ras and Trp53 mutations in
pancreas to dietary Garcinol. This pancreatic mouse model reflects a close picture of
the human disease with the full array of lesions including early PanINs developing into
aggressive PDA and metastasis to lymph nodes and other organs. Dietary Garcinol
improved survival of KPC mice, with all the mice within the group surviving 6 weeks of
study. Garcinol alone was able to halt the progression and reduction in size of some of
the tumors monitored by MRI and ultrasound. In combination with Gemcitabine the
response to drug increase from 10-15% to 25%, Indicating the potential of Garcinol in
adjuvant therapy
No adverse changes to red blood cells, white blood cells and overall blood
morphology were noted after the Garcinol diet. NK&NKT cell ratio was found to be
increased in Garcinol treated group, upon investigation of blood smears from these
mice. This is a very interesting finding and warrants detailed investigation. KPC mice
develop lower esophageal and fore-stomach papillomas [32]. These papillomas may be
due to its pdx component in the genetic background related to gut development [32], or
else can be due to genetic instability including SMAD expressions[37], leading to
complications and death in many cases of these mice due to intestinal obstruction.
Garcinol ingestion reduced these papilloma formations in treated mice improving overall
inflammation and patency of the foregut, vital for nutrition of these severely ill mice.
Histological investigation of pancreatic tissue correlated with the MRI Ultrasound
findings. Minimum number of mouse pancreatic intraepithelial neoplasia was found in
Gemcitabine plus Garcinol combination group. Progression of mPanIN 1 to mPanIN 3
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was observed to be retarded in Garcinol treatment group with lower number of mPanINs
in mPanIN3 grade. Further exploration of Paraffin embedded pancreatic tissue with
S100P antibody, a protein overexpressed in pancreatic cancer tissue but not in normal
pancreas, opened up new doors for studying KPC mice pathology. S100P expression
very well correlated with mPanIN grading and advancement to aggressive pancreatic
ductal adenocarcinoma in KPC mice. Labeling of S100P validated the H&E findings in
different groups. Although mutation in DPC4 and other tumor suppressor genes were
not found to be signature of this model[32], exploration of DPC 4 expression in the
pancreatic tissue with immunohistochemistry revealed that there was considerable loss
of

DPC4 expression in advanced mPanIN, Pancreatic ductal adenocarcinoma and

surrounded tissue compared to healthier acinar and ductal tissue. Garcinol treated mice
showed improvement in the architecture of lobular structure and preservation of acinar
and ductal organization confirmed with normal expression of DPC4. Coherent with
findings on invitro effects of Garcinol on Pancreatic cancer cell lines from our lab, invivo
anti-cancer effects of Garcinol has been elucidated in this study.
Dietary Garcinol has modulated the microRNA microarray profiles in favorable
manner, many of the tumor promotor miRNA were observed to be down regulated after
treatment. Additionally multiple tumor suppressor miRNA have shown higher
expressions after Garcinol ingestion for just 6 weeks. We investigated some of the
target gene pathways of these altered microRNA, to Study the gene regulations by
microRNA and regulation of microRNA by some genes like Notch1 have been reported
by earlier studies to regulate miR451 expression. CCND1, MMP9, and notch1 showed
reduced expression in Garcinol treated group in pancreatic tissue. One of the first
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metastatic site, liver also showed reduction of CCND1 and MMP9. These results
necessitate further investigation of pathways and molecular mechanism involved in
down regulation of these genes, based on our miRNA data and mRNA data we propose
that miRNA 451a, miRNA 23a and other microRNAs statically differently expressed,
could be involved in epigenetic modulation of gene expressions in P53 and kras
mutated pancreatic cancer mouse model.
Urinary metabolomics profiles of the Garcinol treated mice showed differences
from KC mice after 6 weeks of treatment as observed by the separation in PCA score
plots. After further investigation, using models with different treatment and control
groups, it was explained that the separation of Garcinol treated mice were in the
direction of Control mice without cancer and KPC mice at the beginning of the study.
These results suggest that Garcinol has improved the urinary metabolomic profiles of
KPC mice indicating slowed progression of the disease. Loading plots directed toward
some of the peaks in the spectra responsible for this improvement. These peaks were
later identified and quantified in the CHENOMX. Compounds which were observed to
be differently expressed included reduction of Allantoin, a known oxidative stress
marker. Increased levels of Phenylacetate and Tartrate.

Taurine levels were also

increased as compared to KC. Serum Taurine levels are reported to be decreased with
progression different cancer types [95] and its increase can reflect improvement in the
disease. Excretion of urea was found to be higher in KC group compared to other
groups this could be indicative of cachexia and muscle protein loss in KC mice.
Results from this study can be investigated in a larger scale animal study
involving larger animals and more number of animals. Further investigation of molecular
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pathways identified can lead to its incorporation as a chemotherapeutic agent in clinical
trial. Beneficial results may lead into a pilot human study. Garcinol showed synergistic
effects with Gemcitabine in some of the investigated pathways, further exploration of
dose and response can be done to optimize this beneficial combination.
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Adenocarcinoma of pancreas is recognized for its poor prognosis, as it
progresses asymptomatically and is rarely diagnosed at early stage. According to
American cancer society pancreatic cancer, it has lowest survival rate in all cancer
types, with less than 6% five year survival rate. Surgical resection is only possible for
20% of diagnosed cases and current chemotherapy has only 15% response rate. Even
the most favored drug, Gemcitabine, increases survival time only by a few months,
depending on the stage at diagnosis. Some bioactive food components or
nutraceuticals have shown chemopreventive and chemotherapeutic effects without
added side effects. Garcinol is a polyisoprenylated benzophenone derivative from
Garcinia Indica fruit extract. Garcinol has shown dose dependent favorable response in
pancreatic cancer cell lines, alone and in combination with Gemcitabine. In this study,
we investigated the invivo effects of dietary Garcinol in a transgenic mouse model of
Pancreatic Cancer (PaCa). This model is considered to be the animal model which best
mimics development of human PaCa. Based on invitro data from our lab we
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hypothesized that Dietary Garcinol treatment will slow down the progression of
Pancreatic Cancer in Kras and p53 transgenic Pancreatic Cancer mouse model. We
had three specific aims. Specific aim 1) To investigate the invivo response of dietary
Garcinol on PaCa animal models and to monitor the tumor progression with MRI. We
also ruled out the possibility of toxicity of dietary Garcinol by blood smears and fore
stomach H& E slides. Additionally we did detailed histological investigation of
Intraepithelial neoplasia lesions in the pancreatic tissue collected at sacrifice. Specific
aim 2, To investigate the mouse pancreatic and liver tissue, for response to the dietary
Garcinol at molecular level. We studied changes in the micro RNA profile of Garcinol
treated vs. non-treated animals and investigated the response of dietary Garcinol on
tumor promoter target genes of miRNAs from different molecular pathways, in pancreas
and a common metastatic liver tissue. Specific aim 3, To investigate the differences in
Urinary Metabolomic profiles of Garcinol treated mice compared to non-treated mice
and Target analysis to identify metabolites responsible for differences. Methods, Six to
eight week old male KPC mice (kras and P53 conditional mutant) were divided into 4
groups( KC- cancer control; KGr- 0.05% Garcinol diet; KGm-Gemcitabine injected;
KGG- Garcinol+Gemcitabine), littermates without mutation served as non- cancer
controls were divided into 2 groups( CC- isocaloric diet, CG- Garcinol diet) . Mice were
fed 0.05% Garcinol added diet or isocaloric diet (Dyets- Bethlehem, PA). Mice were
individually housed. Body weight were measured twice/week from week 1 to week 6.
Two groups received Gemcitabine weekly injections (100mg/kg- intraperitoneal
injections) up to 5 week. MRI T2 weighted image scans were conducted on 7T scanner
(ClinScan, Bruker, Karlsruhe, Germany) in week 1 and week 5 of the study. Urine
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samples were collected in week 2, 4 and 6 for metabolomic analysis. Mice were
euthanized in week six of the study and tissues were collected. Blood smear slides were
prepared at the time of sacrifice and after drying were fixed in 95% Ethanol. The smears
were stained with Wright Giemsa Stain and observed under the microscope (Nikon
Eclipse 80i). Pancreatic tissues was fixed in 10% neutral buffered formalin and then
transferred to 70 % ethanol before staining. H&E stained slides were prepared and
observed under microscope (Nikon Eclipse 80i). Specific immuno histostaining (IHC)
with S100P and DPC4/SMAD4 was performed to confirm the findings. MicroRNA array
analysis was conducted and some miRNA were validated by RTPCR. Some of the
target genes of miRNA identified to be differently expressed were investigated by
RTPCR. Nuclear Magnetic resonance spectroscopy was performed on Varian-500S.
Simca P+ and CHENOMX NMR suite were used for Metabolomic analysis of urinary
spectra. Results, Dietary Garcinol arrests the Progression of Pancreatic Cancer invivo
in KRAS and p53 pancreas- specific mutant mouse model. All the mice in Garcinol
group survived the 6 week study, with 75% survival in KGm and KGG. We observed
tumor reduction in KGr, KGm and KGG groups. There was no toxicity observed to the
blood in blood smears with Garcinol treatment, NK and NKT cell were found to be in
higher percentage in KGr group compared to KC group. No toxicity to Garcinol was
observed in fore stomach H&E slides, additionally we observed reduced papilloma
formations in KGr group compared to KC group. Reduction in total number of
Pancreatic intraepithelial neoplasia (mPanIN) was observed in both Garcinol treated
groups with lowest number of mPanIN 3 in KGG group indicating slowed progression of
mPanIN

1 to mPanIN 3. Histology findings were confirmed with specific immuno-
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histostaining with S100P and DPC4/SMAD4 antibodies. MicroRNA microarray data
showed down regulation of multiple tumor promotor miRNA and up regulation of several
tumor suppressor miRNA with Garcinol treatment. Lower expression levels of miRNA
23a and higher expression levels miRNA 451a after Garcinol treatment were validated
by RTPCR. Relative mRNA expressions levels of MMP9, CCND1 and Notch1 were
found to be decreased in KGr and KGG groups compared to KC group in pancreatic
tissue samples. Relative expression levels of CCND1 were decreased in KGr and KGG
groups in Liver tissue samples. MMP9 relative expression levels showed reduction in
Garcinol treated groups KGr group. Relative expression levels of Bcl2 were found to be
decreased in KGr, KGm and KGG groups. Urinary metabolomics profiles from week 6
Garcinol treated group were closer to non- cancer and week 2 of non-treated KC group.
Target analysis with CHENOMX identified Taurine, Tartrate and Phenylacetate to be in
higher concentrations in Garcinol treated group compared to non-treated group and
Allantoin was found to be lower in Garcinol treated group compared to KC non-treated
group. This invivo dietary Garcinol study has highlighted anti-cancer potential of this
bioactive food component. Our data indicates that dietary Garcinol retarded pancreatic
cancer progression in transgenic pancreatic cancer mice. Garcinol has shown pleotropic
effects, targeting multiple tumor related pathways. Further investigation of molecular
pathways identified can lead to its incorporation as a chemotherapeutic agent in a
clinical trial.
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